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ROLE OF OBESITY IN MODULATING THE IMMUNE SYSTEM 
ROMAN FAYNGERSH 
ABSTRACT 
 
INTRODUCTION: Diet induced obesity (DIO) is a major driving force responsible for 
low-grade inflammation mediated immune system decline. Impaired immune defenses 
lead to a number of chronic diseases and ultimately to an increased mortality. 
 
DISCUSSION: Over half a billion people worldwide are considered overweight or 
obese. It has been estimated that $190 billion dollars was spent in the US on obesity-
related healthcare costs just in 2005. Lower productivity, lost wages, higher insurance 
costs, and an increased strain on the healthcare system as a whole, are the hallmarks of 
the obesity epidemic. Considerable body of epidemiologic evidence implicates DIO as 
the major cause of numerous pathologies. The obese population doesn’t just suffer 
increased mortality from chronic conditions such as, cardiovascular disease, pulmonary 
diseases, Type 2 diabetes, various cancers, hyperlipidemia, hypertension, non-alcoholic 
fatty liver disease (NAFLD), renal failure, osteoarthritis and many other slow-onset 
diseases. Obese individuals also have increased mortality for more acute conditions such 
as N1H1 influenza virus, allergic diseases, and post-surgical complications while also 
lowering the efficacy for vaccinations and Helicobacter pylori eradication therapies. 
Today scientists recognize adipose tissue as the largest endocrine organ in the human 
body, releasing a myriad of paracrine and endocrine molecular factors. During DIO these 
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adipocytokines induce a proinflammatory switch in the adipose tissue machinery, 
initiating chronic low-grade inflammation. Sensing an ongoing attack the immune system 
responds trying to maintain homeostasis. DIO however, initiates a positive feedback loop, 
which perpetuates inflammation and further decimates immune system’s capacity to 
resist threats and to restore order. 
 
CONCLUSION: While the basic obesity-inflammation-disease road map has been 
outlined, many questions remain. Multiple areas of immunometabolism and meta 
inflammation require deeper understanding, but two key recommendations for future 
studies stand out. First, since it is easier to prevent obesity than to reverse it, attention 
should be focused on elucidating the endocrine role of foodstuff. Second, to find cures for 
chronic conditions of the ever growing obese population, scientists must elucidate the 
mechanism of obesity-induced inflammation’s function in diminishing immune system’s 
capacity. 
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INTRODUCTION 
 
 Even ancient Greeks knew that man’s diet is the key to his health the diseases that 
afflict us. Hippocrates could not have known how far ahead of his time he was when 
2400 years ago he stated: “Let food be thy medicine and medicine be thy food”. Diet has 
an immense impact on our health, yet there is no scientific consensus on the underlying 
links between what we eat and the infections and the diseases that afflict us. The question 
this thesis attempts to address is the role obesity plays in modulating diseases via its 
interactions with the immune system. In the past two decades there has been an enormous 
amount of research linking Diet Induced Obesity (DIO) with many pathophysiologies. 
While scientists have yet to uncover the “smoking gun”, the obesity epidemic is 
progressing at a brisk rate. Between 1980 and 2008 the worldwide number of obese 
(BMI>30 kg/m2) individuals has nearly doubled to more than half a billion people  
(WHOb |, n.d.). That is equivalent to the population of North and Central America 
combined (“The World Bank. Population, total | Data Table.,” n.d.). For the first time in 
history the worldwide number of overweight people has surpassed the number of 
underweight individuals (Finucane et al., 12). Excess body weight is implicated as a risk 
factor for mortality and morbidity for nearly 3 million people annually (WHOb, n.d.). 
One third of the worlds’ population (34.3%) has a body mass index (BMI) of 25 kg/m2 or 
greater (WHOb, n.d.), classifying them as overweight, obese or extremely obese 
according to the NIH guidelines (“NIH. NHLBI. Obesity Guidelines. Body Mass Index 
Table 1.,” n.d.). Surprisingly, it does not take many years of overnutrition, to markedly 
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increase the size of the individual’s adipose tissue. A recent study by Gupta et al. 
demonstrated that a caloric excess, even in the short term, results in a significant increase 
in body fat and visceral adipose tissue volume (Gupta et al., 2013). During this study, 
healthy, young, mean age 28.4 years old, volunteers were overfeed for eight weeks, 
resulting in a 30% increase in subcutaneous adipose tissue and an even more astounding 
103% increase in visceral adipose tissue. Also noted was an average BMI increase of 2.5 
points, as well as an increase in a litany of important biomarkers of inflammation and 
cardiovascular disease (Gupta et al., 2013). 
 The effect of overnutrition on multiple organ systems has its roots in the 
hominids’ evolutionary machinery. Our ancestors, who had to survive through constant 
food scarcity, under the evolution exerted pressure, became highly efficient at extracting 
and storing food derived energy. Over 40 years ago, James Neel - a preeminent 
geneticist, suggested that 
 
“a ‘thrifty genotype’ had evolved to protect human populations from 
starvation facilitating quick release of insulin, efficient conversion of 
sugar and storage of excess energy as body fat during the rare times of 
food abundance” (Neel, 1962). 
 
 Biological and cultural changes, such as increased physical activities, expanding 
brain size and fertility requirements created selection pressures and necessitated the 
switch to a more energetically dense foodstuff. Further brain size increase might have 
been facilitated by invention of agriculture and the introduction of cooking, making food 
more digestible, allowing easier access to nutrients and calories (Aiello & Wheeler, 
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1995). As brain development involves phospholipids-associated organization of synapses, 
it is not unreasonable to consider that genes promoting greater energy efficiency may 
have co-evolved with those influencing evolution of the large human brain (Erren & 
Erren, 2004). The next developmental step was brought about by the advent of modern 
agriculture, the discovery of electricity and the invention of refrigeration. In evolutionary 
terms the switch from a permanent caloric deficit to a caloric abundance, happened 
instantaneously. Human’s inability to rapidly reverse millennia of evolutionary selection 
and turn down the metabolic machinery to accompany the new energetic homeostasis is 
leading to what World Health Organization (WHO) is calling a ‘globesity’ epidemic 
(WHOa, n.d.). 
 Current scientific consensus points to the most basic cause of obesity as the 
energy intake that exceeds energy expenditures. The incoming calories are converted and 
stored as energy in the form of white adipose tissues (WAT). The unique structure of 
unilocular adipocyte, the building block of WAT, is responsible for its uncanny ability to 
greatly increase in size during times of caloric abundance. Along with other organelles, 
adipocytes contain intracellular lipid droplets (LDs) and while LDs are ubiquitous and are 
present in all types of eukaryotic cells, they have a very different structure in the white 
adipose tissue. Non-adipocyte cells usually contain many tiny LDs, typically with a 
diameter of less than 1 µm, while WAT adipocytes coalesce TAGs into one massive LD, 
that is in 100+ µm range and occupies 95% of the intracellular space (Fujimoto & Parton, 
2011; Suzuki et al., 2011; Brasaemle & Wolins, 2011). It is interesting to note that while 
increasing adipose cell size 10 fold, from 20 to 200 µm, increases cells’ lipid content by a 
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factor of a 1,000 (Jo et al., 2012). Superbly adopted and primed by evolution to store 
excess energy the results of the previously mentioned overfeeding study by Gupta et al. 
shouldn’t be surprising, where the subcutaneous adipose cells significantly increased in 
size, from 0.596(0.91) to 0.919(0.1) ρL (Gupta et al., 2013). In a certain sense the fat cell 
is a perfect storage medium to accumulate potential energy. 
 Modern industrial societies have achieved the ultimate foraging strategy by 
maximizing energy intake and minimizing physical effort and energy expenditure, but the 
tradeoff is a decline in nutritional health. Obesity is linked to diseases of cardiovascular, 
renal, pulmonary and endocrine systems, as well as, type2 diabetes, insulin intolerance, 
osteoarthritis, asthma, immune paralysis, periodontitis, cognitive decline and multiple 
other ailments (Xu et al., 2003; Ciesla et al., 2006; Kelly et al., 2008; DeFronzo, 2010; 
Lönn et al., 2010; Suvan et al., 2011; Barrette & Schwertani, 2012; Kim et al., 2011; 
Jämsen et al., 2012; Cazzola et al., 2013; Gupta et al., 2013; Liu et al., 2013; Mancuso, 
2013; Yau et al., 2014). Considering the far reaching implications of obesity, the large 
amount of research scientists are generating should not be surprising. This thesis will 
attempt to elucidate the impact of diet induced obesity on humans, by evaluating whether 
overweight individuals immune system fairs worse, same, or better than in their lean 
counterparts and secondly to suggest possible mechanisms leading to inflammation and 
to the disease state. 
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PUBLISHED STUDIES 
 
Epidemiological Studies 
 Epidemiological and observational studies are the best available tools to track and 
test hypothesis of viral/bacterial infections in a population. Aggregation of this 
information offers a glimpse into the effects an infectious load has on the overweight and 
obese demographic. There has also been considerable scrutiny of the animal models and 
numerous in vitro experiments in the past decade, all in an effort to elucidate a link 
between the immune system, the myriad of obesity influenced diseases and the positive 
energy balance of the overweight and obese individuals. 
 
Obesity and H1N1 
 
 In 2009 a novel flu virus appeared in Mexico and The United States, presenting a 
perfect opportunity for the scientist to observe and study infectious load’s impact on the 
different strata of the population. Since then, there have been multiple studies reporting 
obesity to be an independent risk factor for increased morbidity and mortality following 
the 2009 influenza A (H1N1) virus. In the early spring of 2009 the first reports of H1N1 
surfaced and by August of 2010 almost 500,000 laboratory confirmed cases of the 
pandemic influenza infection have been recorded, with over 18,000 deaths worldwide 
(Miller et al., 2010; WHOd,2009). 
 A noteworthy review was conducted following the 2009 H1N1 flu outbreak, 
looking at six cross-sectional studies. This meta-analysis has shown that for patients 
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hospitalized for 2009 H1N1 influenza viral infection, obesity doubled the risk of critical 
care unit admission and/or death, with a much stronger associations for morbidly obese 
individuals (Fezeu et al., 2011). In this meta-review Fezeu and colleagues included 
studies which published obesity data among hospitalized participants having pandemic 
influenza A (H1N1) infection and who were either admitted to the intensive care unit or 
died. These inclusion criteria identified 149 articles in PubMed, with a total of six eligible 
studies to be included in this review. In all, 3059 subjects were hospitalized for influenza 
A (H1N1) viral infection. Morbidly obese H1N1 patients, BMI index ≥ 40 kg/m2, were 
twice as likely to be admitted to ICU or die (OR 2.01, P<0.002) and obese patients, BMI 
index ≥ 30 kg/m2, had an over two fold non-significant increased likelihood risk of ICU 
admission or death (OR 2.14, P<0.07) (Fezeu et al., 2011). Obese patients were compared 
to the control group of lean individuals hospitalized with the same H1N1 viral infection. 
The limitations of this study centered on a limited patient data, leading to an inability to 
distinguish associations by age class. Authors were not able to adjust for baseline 
conditions such as respiratory functions, because these were not available in the pooled 
data and authors did not have access to the individual patient data. 
 Another prospective cohort study by Viasus et al. conducted between June and 
November of 2009, tried to identify factors associated with composite outcome of 
intensive care unit admission or in-hospital mortality, among adults with confirmed 
pandemic influenza A (H1N1) virus infection. Scientists found that morbidly obese 
patients (BMI > 40 kg/m2) had a higher risk of severe disease (OR, 6.74; 95% CI, 2.25-
20.19) (Viasus et al., 2011). A California study conducted in the November of 2009 
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concluded that more than half (52%) of patients hospitalized with influenza (H1N1) 
virus, were obese (BMI ≥ 30kg/m2), and more than a third (40%) were morbidly obese 
(BMI > 40kg/m2). Percentages are even higher for the obese patients in the fatal cases, 
66% of obese and 50% of morbidly obese patients (Louie, 2009). As a reference point, 
according to the results from the 2009–2010 National Health and Nutrition Examination 
Survey (NHANES), the percent of US adults who were obese is thirty five and morbidly 
obese is six (Fryar et al., 2012). 
 A study by Van Kerkhove et al. looked at the information compiled by the WHO 
from the surveillance programs of the 2009 flue pandemic supplied by its member states, 
trying to assist policy makers in determining especially vulnerable risk groups for 
targeted preventive measures. Looking through 70,000 laboratory confirmed H1N1 
influenza cases, among other risk factors, the study found obesity to be a major 
contributor to the three levels of severity of illness: hospitalization, admissions to ICU, 
and fatalities. The proportion of patients with obesity increased with increasing disease 
severity, and the pooled OR for death given hospitalization for obesity (BMI ≥ 30kg/m2) 
was 2.9. Available data from the two member states supplying the necessary data, 
indicated the risk of death associated with morbid obesity (BMI > 40 kg/m2) was 
increased (RR = 36.3) relative to the general population. One of the limitations of this 
study was its inability to get more granular patient data, as many countries were not 
willing to have their country-specific data compared with others (Van Kerkhove et al., 
2011).  
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 Two compelling studies looked at the worldwide deaths associated with the 
influenza A H1N1 pandemic, extrapolated from the pooled WHO country data. First, a 
study published in 2012 by Darmwood et al, estimated a total of 151,700 – 575,400 
pulmonary and cardiovascular deaths worldwide associated with the influenza virus 
(Dawood et al., 2012). And in the second, published in the fall of 2013, Simonsen et al. 
estimated that there was a 300,000 – 400,000 all-cause mortality rate in the under 65-yr-
old cohort and the respiratory specific mortality that was approximately ten times higher 
than the WHO laboratory confirmed census data (Simonsen et al., 2013). Overall these 
numbers are significantly (8 – 31 and 16 – 22 times) higher, respectively, than those 
results reported in the WHO statistics. These studies used distinct methodology and 
applied different statistical modeling techniques, which only strengthen their combined 
assertions of a higher than reported real influenza associated death toll. Researchers did 
not present comorbidities stratified data, but given the numerous studies showing an 
epidemiologic link between obesity and H1N1 influenza virus, increased severity of 
influenza virus outcomes in the overweight population is all but guaranteed. 
 These data clearly indicate that the overweight and obese population (BMI > 25 
kg/m2) was at a higher risk for contracting the influenza pandemic (H1N1) virus, than the 
non-overweight patients (BMI < 25 kg/m2). A possible explanation of the link between 
obesity and severe outcomes is the prevalence of the preexisting conditions in this subset 
of the population. There could have been direct causation (flu overwhelmingly strains the 
pulmonary systems), indirect causation via other risk factors (cardiovascular disease, 
asthma, diabetes, renal disease, GI disorders, etc.), or a non-causal association (genetic, 
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dietary). To establish these links researchers require much more granular patient records, 
which are not made available for the broad epidemiologic studies. 
 It appears that besides humans, obese mice were also susceptible to the same 2009 
influenza virus. O'Brien et al. demonstrated that both genetically and diet-induced obese 
animals, independent of the viral strain, were more susceptible to developing severe 
infection (O’Brien et al., 2011). Even prior to the 2009 influenza epidemic, scientists 
knew that obese mice had an altered immune response and were more likely to die from 
exposure to the influenza virus. In 2007 a study by Smith et al. indicated that high BMI 
impairs immunological response to the influenza infection. Even postinfection, obese 
mice had a 6.6 times higher mortality rate (Smith et al., 2007). 
 Unfortunately pleiotropic actions of obesity are not limited to the influenza 
infections - copious epidemiologic data implicates obesity in a myriad of acute and 
chronic conditions. 
 
Obesity and High Blood Pressure 
 
 In January of 2013, the Obesity Society and the American Society of 
Hypertension published a position paper to inform physicians of the association between 
obesity and high blood pressure. The authors concluded that obesity-related hypertension 
is an important public health issue worthy of an extensive review (Landsberg et al., 
2013). The link between obesity and high blood pressure was demonstrated as far back as 
the early 1960s, in the Framingham Heart Study, and today it is estimated that at least 
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75% of the incidence of hypertension is tied directly to obesity (Kannel et al., 1967; 
Lloyd-Jones et al., 2009). A 2004 study looked at 1999-2000 NHANES data, and 
concluded that prevalence of hypertension for the normal weight individuals (BMI < 25 
kg/m2) is 15.3%, while the overweight and the obese populations have a 42.5% and a 
27.8% prevalence of hypertension, respectively (Wang, 2004). A more recent study 
examining the 2007-2010 NHANES data indicated that the odds of high blood pressure 
were about 1.6 times higher among overweight individuals (BMI ≥ 25 kg/m2  to < 30 
kg/m2), and 3.0 times higher for obese individuals ( BMI ≥ 30kg/m2) as compared to 
individuals of normal weight (BMI < 25 kg/m2) (Ostchega et al., 2012). 
 
Obesity and Urinary Tract Infections 
 
 Obesity has been implicated in increased risk of urinary tract infections (UTI). A 
study published in 2011 evaluated records of over ninety five thousand patients 
diagnosed with UTI. Researchers concluded that as a group, the obese were up to 2.5 
times more prone to urinary tract infections (Semins et al., 2012) while another looked 
into association between UTI and obesity, and whether this association is independent of 
diabetes mellitus and vitamin D or 25(OH)D levels (Saliba et al., 2013). Research 
showed that in males, obesity was independently associated with UTI, and in females, 
while it was independent, the association was confined to the group with a BMI ≥ 
50kg/m2 and was not statistically significant (p=0.187). 
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Obesity and Pancreatic cancer 
 
 Pancreatic cancer is one of the deadliest cancers, with a very low five year 
survival rate, estimated to be 6% (Bracci, 2012). A recent overview of the epidemiologic 
data, considered latest evidence and previously conducted reviews, concluded that 
obesity is a modifiable risk factor that is directly associated with the increased risk of 
pancreatic cancer compared to non-obese patients. Bracci suggested that diabetes, a 
common complication arising from obesity, maybe the pathway linking BMI and 
pancreatic cancer (Bracci, 2012). One other paper alluded to a link between obesity and 
pancreatic cancer through diabetes and that aggressive treatment of diabetes might reduce 
the risk of cancer among individuals with pancreatogenic diabetes (Andersen, 2013). 
Additionally, Gukovsky et al. considered how inflammation mediates the pathogenic 
effects of defective autophagy and obesity in pancreatic cancer patients. Gukovsky 
concluded that obesity, amplifies the severity of pancreatitis, and creates the environment 
that promotes the development and progression of pancreatic ductal adenocarcinoma 
(Gukovsky et al., 2013). 
 
Obesity and Myelodysplastic Syndrome 
 
 Ma et al. correlated high BMI to a risk of the development of preleukemia. The 
study concluded that obesity is a risk factor for Myelodysplastic Syndrome (MDS), with 
a more than 2-fold increased risk for the obese (BMI > 40 kg/m2) and a significant 
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positive correlation between BMI and MDS for all overweight, obese and morbidly obese 
individuals (P for trend < 0.001) (Ma et al., 2009). 
 
Obesity and Asthma 
 
 The association between asthma and obesity is ambiguous, nevertheless, there is 
substantial epidemiologic evidence linking them together. A systematic literature review 
concluded that not only is obesity associated with asthma, but it also increases the 
severity of the disease and lowers response to treatment (Ali & Ulrik, n.d.). Another 
review by Liu et al. examined the correlation between asthma and prevalence of obesity 
in children, looking at published literature between 1966 and 2011. Out of 35 included 
studies, 27 reported a positive correlation between obesity and asthmatic symptoms. 
Authors also point to accumulating evidence suggesting an obesity asthma connection 
through non-allergic pathways (Liu et al., 2013). A study evaluated Italian adults, 
examining the link between obesity, asthma and smoking. Scientists found increased 
prevalence of asthma in overweight and obese individuals regardless of their smoking 
status (Cazzola et al., n.d.). 
 
Obesity and Helicobacter Pylori 
 
 Scientists looked at the eradication rates of Helicobacter pylori (H. pylori) in 
obese patients, prior to undergoing bariatric surgery. In 55% of overweight/obese patients 
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(BMI ≥ 25 kg/m2) the treatment was successful, versus an 85.4% success rate for the 
control group (p<0.005). Authors stated that the 30.4% difference between treatment 
groups was not only statistically significant (p = 0.0059) but was also clinically 
important (Abdullahi et al., 2008). In an interesting side note, a more recent study with 
respect to the difference in the rate of H. pylori eradication between Portuguese obese 
patients from 2006 and 2010 concluded, that the overall efficacy of the antibiotic 
treatment has gone down below the current medical consensus, mainly due to the bacteria 
developing drug resistance. It seems that the first-line clarithromycin-based Maastricht III 
consensus eradication is no longer viable in bariatric patient (Cerqueira et al., 2013). 
 
Obesity and Liver Disease 
 
 Liver disease is a growing clinical burden and is a rising health concern in both 
pediatrics and adult care. Population-based studies have indicated obesity as the chief risk 
factor for pediatric NAFLD (non-alcoholic fatty liver disease), while others point to the 
link between BMI and prevalence of NAFLD in adults and progression of chronic 
hepatitis B and C virus as well as hepatocellular carcinoma (HBV, HCV and HCC, 
respectively) (Neuschwander-Tetri & Caldwell, 2003; Loannou et al., 2005; Chen et al., 
2008; Wong et al., 2009; Everhart et al., 2009; Liu et al., 2010; Wang et al., 2010; 
Berzigotti et al., 2011;Lee et al., 2011; Armstrong et al., 2012; Wiegand & Berg, 2013; 
Giorgio et al., 2013). The most common causes are alcoholic and non-alcoholic fatty liver 
disease (AFLD & NAFLD), and viral hepatitis infections (“European Liver Transplant 
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Registry - ELTR,” n.d.). The initial hepatic necro-inflammation progresses to hepatic 
fibrosis, which evolves into cirrhosis and can ultimately morph into hepato-cellular 
carcinoma (HCC). German autopsy studies have revealed presence of fatty liver 
pathology in 70% of overweight and 35% of normal weight individuals (Wiegand & 
Berg, 2013). Cirrhosis and HCC due to chronic HBV and HCV infections are among the 
leading causes for the liver transplantation in the developed countries (Adam et al., 2003; 
Wiesner et al., 2003; Sugawara & Makuuchi, 2006). In Europe they have accounted for 
almost 40% of liver transplants in the past twenty years (“European Liver Transplant 
Registry - ELTR,” n.d.). In US the numbers are even more alarming. At the end of 2011, 
almost 80% of patients awaiting liver transplant had liver pathologies due to non-
cholestatic cirrhosis, metabolic diseases or malignant neoplasms (“Scientific Registry of 
Transplant Recipients. Table 9.1C. Waiting List Patient Characteristics at Year-End Liver 
Waiting List. All Waitlist Patients, 2002-2011,” n.d.). Obesity is often associated with 
cryptogenic liver diseases and is a noteworthy factor in progression and response to anti-
viral treatments for hepatitis (Chen et al., 2008; Berzigotti et al., 2011). A 2011 study 
showed that, increased body mass, as measured by BMI, is a strong and an independent 
(p=0.02) predictor of decompensation in patients with compensated cirrhosis, as well as a 
positive correlation trend between BMI and the development of decompensation 
(Berzigotti et al., 2011). Authors also made an interesting epidemiologic observation, two 
thirds of their patients were overweight or obese, a proportion similar to the general 
population. Another 2011 study looked at the impact of BMI and viral load on liver 
histology in individuals with hepatitis B antigen-negative chronic infections. Findings 
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from this study suggest a synergistic effect of BMI and hepatitis B virus replication on 
disease progression, and are both independent of all well-established concomitant factors 
(Lee et al., 2011). The overarching theme is the link between infectious liver pathologies, 
NAFLD and BMI, as obesity’s link to the liver disease is coming into focus through 
chronic inflammatory processes. 
 
Obesity and Transplant Surgery 
 
 There have been studies concerned with wound complications following 
transplant surgeries. A study completed in Poland found that donor’s BMI was an 
important factor in post pancreas-kidney transplantation surgical complications (Ziaja et 
al., 2011). Another study uncovered a connection between post surgery wound 
complications not only in overweight patients, but also in patients with a history of 
significant weight loss, over 10kg (Kuo et al., 2012). Authors conjectured that the 
adverse outcomes are related to the changes of the abdominal panniculus. BMI over 30 
kg/m2 is a risk factor for transplant renal artery stenosis (TRAS), this is one of the 
reasons medical centers take extreme caution when considering transplantation in obese 
patients (Kamali et al., 2010). 
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Obesity and Inflammation 
 
 A few international studies have looked at the link between obesity and white 
blood cell (WBCs) counts, the premise here is the interconnectedness of BMI, 
inflammation and immune response. An epidemiological study looked at WBC counts in 
obese females. They reported a highly significant, direct correlation between increasing 
BMI and platelet count (p=0.009), leukocytes (p<0.000) and neutrophils (p=0.001). 
Researchers did caution that not all innate immunity cells measured in this study showed 
correlation with the BMI (basophils, eosinophils, monocytes, NK cells) (Al-Sufyani & 
Mahassni, 2011). Other studies have confirmed the trend line of increased WBC count 
with increased BMI (Sekitani et al., 2010; Chae et al., 2013; Marzullo et al., 2014). 
 
Obesity and Other Diseases 
 
 There have been a number of studies pointing to obesity as a factor in increased 
prevalence of diseases. Obesity has been linked to increases in allergic diseases in 
children (Kusunoki et al., 2008; Visness et al., 2009; Murray et al., 2011). There has been 
research indicating that obese patients have a depressed cytokine response to blunt injury, 
remained in metabolic acidosis longer than normal BMI patients, are more prone to post-
resuscitation multiple organ failure (MOF), and have increased post-injury morbidity 
(Ciesla et al., 2006; Winfield, Delano, Lottenberg, et al., 2010; Winfield, Delano, Dixon, 
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et al., 2010; Nelson et al., 2012; Winfield et al., 2012). An Australian population-based 
prospective cohort study indicated that obesity is partly associated with 50%-60% greater 
risk of pertussis notification (Liu et al., 2012). Another epidemiologic study found that 
overweight and obese pregnant women have a greater risk of developing complications 
pre and postpartum, versus their normal weight counterparts. Neonates of women with 
BMI > 25 kg/m2 have a higher chance of developing complications (El-Gilany & 
Hammad, 2010). While this study does not prove direct causative relationship between 
obesity and adverse maternal and perinatal risks, it does add to the existing evidence 
suggesting a possible link. 
 Considering its impact and the overwhelming epidemiologic data suggesting a 
correlation between obesity and various diseases and infections, the question becomes, 
why are overweight and obese individuals more vulnerable? 
 
Events that turn on Diet Induced Obesity. 
Food as a hormone 
 
 To begin addressing this dilemma we need to consider the adipose tissue. Every 
human being walking the earth has adipose tissue, however, not every human possessing 
adipose cells becomes overweight or develops obesity and its deleterious effects. Dr. 
Francis Collins, Director of the National Institutes of Health (NIH) and former Director 
of the National Human Genome Research Institute (NHGRI) succinctly stated: “Genetics 
loads the gun and environment pulls the trigger”. Present scientific consensus points to 
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two common pathways leading to obesity, most likely there is a third pathway which is 
the combination of the two. First do we become obese by inheriting genes resulting in 
anomalies in the metabolic machinery that lead to energetic imbalance and the storage of 
overabundance of consumed calories. Second is improper diet, leading to the changes in 
the underlying cellular machinery a key factor in obesity development. This second 
pathway is aptly named Diet Induced Obesity (DIO), as it turns on the obesity switch 
epigenetically and is presently under increased scrutiny for it is an easily modifiable risk 
factor across multiple demographics. This view is supported by the growing body of 
evidence suggesting that food acts as a hormone and that WAT is the biggest endocrine 
organ in the human body. Although food isn’t produced in the body, but is rather 
externally sourced, its components are carried throughout the body by blood and act as 
signaling molecules analogously to the endogenously produced hormones (Hirai et al., 
2010; Ryan & Seeley, 2013). In broad terms, hormones influence target tissues by acting 
on cell-surface receptors, activating cellular cascades that alter activity of the intracellular 
pathways or via nuclear receptors that control gene transcription. 
 An example of such interaction comes from omega-3 fatty acids (n-3 PUFA), 
found in fish, certain vegetables, nuts and grains. Epidemiological studies have long 
touted cardioprotective properties of omega-3 fatty acids, but simple biochemistry cannot 
explain why n-3 PUFA should lead to benefits compared to other fatty acids. Omega-3s 
are known to increase arrhythmic thresholds, decrease blood pressure, improve arterial 
and endothelial function, reduce platelet aggregation, favorably affect autonomic tone 
and reduce inflammation (Kromhout et al., 2011). Among its many targets, omega-3 fatty 
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acids could down-regulate the activity of nuclear factor (NF)-kβ, which is a key player in 
the inflammatory response and is partially responsible in the pathogenesis of 
cardiovascular disease (CVD). NF-kβ is sequestered in the cytoplasm bound to the 
protein inhibitor-kβ (I-kβ). In response to inflammatory stimuli (cytokines, 
lipopolysaccharide (LPS), viruses) I-kβ is phosphorylated and is released, thereby freeing 
NF-kβ, which in turn translocates into the nucleus. In the nucleus nuclear factor-kβ 
modulates expression of genes responsible for the inflammatory signaling pathways 
(upregulation of Interleukin (IL)-1β, IL-2, IL-6, IL-12, tumor necrosis factor alpha (TNF-
α), GM-CSF (Granulocyte-macrophage colony-stimulating factor), MCP-1 (monocyte 
chemoattractant protein 1), MIP-1α (Macrophage Inflammatory Proteins 1 alpha), iNOS 
(inducible nitrix oxide synthase), COX-2 (Cyclooxygenase 2), PLA2 (Phospholipase A2), 
ICAM-1 (Intercellular Adhesion Molecule 1), VCAM-1 (Vascular cell adhesion protein 
1), etc.) (Adkins & Kelley, 2010; “Gilmore, Thomas (n.d.). Boston University Biology 
Department. "NF-kB Target Genes"). Omega-3 fatty acids inhibit phosphorylation of 
inhibitor-kβ (I-kβ), thereby halting release and translocation of the NF-kβ and its ability 
to induce transcription of proinflammatory factors (Zhao et al., 2004). Another recent 
study using n-3 PUFA, is emphasizing Th17 cells and IL-17A connection to DIO 
inflammation. Monk et al. hypothesized that n-3 PUFA, would decrease the expression of 
inflammatory genes and lower the number of circulating inflammatory immune cells in 
the concurrent obesity and colitis model (Monk et al., 2012). The decrease in 
inflammatory markers was noted in many inflammatory cytokines (MCP-1, 
IFNγ(Interferon gamma), IL-6, IL17F and IL-21), but more importantly, his group saw a 
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considerable decline in mRNA (Messenger RNA) expression of the Th17 cell master 
transcription factor (RORγτ) and key inflammatory factors (IL-6, IL-17A, IL-17F, IL-21, 
IL-23 and IFNγ) (Monk et al., 2012). These results expand our understanding of the ways 
food derived molecules suppress Th1/Th17 cells and proinflammatory adipose tissue 
macrophages (ATMs), via reconfiguring the inflammatory gene expression. 
 Peroxisome proliferator-activated receptors (PPAR), which includes multiple 
isoforms (α, γ , δ), are a group of ligand-regulated nuclear receptors that form 
heterodimers, along with retinoid X receptor (RXR), and bind to the promoter region of 
the target genes involved in lipid metabolism and inflammation. Activation of PPARα 
and PPARδ has the ability to inhibit NF-kβ activation, leading to decreased expression of 
the proinflammatory factors IL-1β, IL-6 and TNF-α (Evans et al., 2004; Touyz & 
Schiffrin, 2006; Álvarez-Guardia et al., 2011). PPARs upregulate Ikβ-α which binds to 
NF-kβ, and prevents binding to the genes’ promoter region (Winther et al., 2005). 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid(DHA), both omega-3 fatty acids, 
are known to be PPARα/δ agonists. Results of a recent computational study via molecular 
dynamics simulation, confirmed very high affinity binding of DHA to PPARs and RXR, 
elucidating DHAs mechanisms of action (Gani & Sylte, 2008). There are other food 
borne compounds that perform similar functions. A compound found in tomatoes, 
lycopene being another example of food turned into a hormone. A study found it to be an 
agonist of PPARγ and as has been discussed earlier, it also inhibits NF-kβ and its 
inflammatory consequences (Palozza et al., 2011). 
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 Other fatty acids act directly on endogenous hormones. For example, once 
activated, ghrelin, a stomach derived hormone, increases appetite, food intake and weight 
by binding to its receptor, growth hormone secretagogue receptor (GHSR). However, in 
order to be activated, a fatty acid side chain needs to be attached to ghrelin and various 
side chains direct different outcomes (Al Massadi et al., 2011). 
 Another example of food acting as a hormone by regulating endogenous activity 
of the gut microbiome and inducing signaling cascades is food derived non-digestible 
oligosaccharides (NDOs). Various types of NDOs naturally occur in milk, honey, fruits 
and vegetables such as onion, asparagus, artichoke, chicory, leek, garlic, yacon, salsify, 
sugar beet, banana, tomato, soybean as well as grains, rye, barley and wheat (Rivero et 
al., 2001; Mussatto & Mancilha, 2007). Of interest is the fact that many NDOs are found 
in the human breast milk, which for millennia was the only nutritional source for 
newborn’s postnatal development (Rijnierse et al., 2011; Marcobal & Sonnenburg, 2012). 
Commensalistic gut bacteria metabolize and ferment NDOs into short-chain fatty acids 
(SCFA), mainly propionate, butyrate, acetate and L-lactate. In adults these SCFAs bind to 
and activate cell-surface receptors, free fatty acid receptor 2, 3 are expressed on 
enteroendocrine L cells that produce the incretin hormone glucagon-like peptide-1 (GLP-
1) (Ryan & Seeley, 2013). 
 Not to be overlooked, the currently ubiquitous carbohydrate-rich foods and 
sucrose loaded drinks are capable of creating a hormonal response as well. These 
nutrients potentiate a robust insulin release and over a prolonged period of time produce 
hyperinsulinemia which upregulates expression of the lipogenic transcription factor 
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SREBP-1c (sterol regulatory element binding protein-1c) and its target enzymes. 
Furthermore, the abundant glucose provides substrate for de novo lipogenesis and as 
such, the excessive calories contain all of the necessary components to get stored as 
triacylglycerol. 
 These studies suggest direct mechanisms whereby food derived molecules, are not 
simply processed to generate energy, but also act in a hormonal capacity to control the 
expression of pro and anti-inflammatory factors that regulate physiological activity. 
Fat as an Endocrine Organ 
 
 It turns out that food is not the only culprit in the etiology of DIO puzzle – white 
adipose tissue itself is part of the problem. Over the last decade researchers have 
uncovered numerous molecular factors through which adipose tissues exerts systemic 
impact on energy homeostasis and projects significant physiologic influence on health 
and disease states. The long-standing belief that the energy storage is adipocytes’ main 
function has fallen by the wayside as scientists have documented a plethora of WAT’s 
paracrine and endocrine secretions, recognizing fat tissues as the largest endocrine organ. 
 Not that long ago, in 1953, Gordon Kennedy proposed that the regulation of food 
intake and energy homeostasis is under influence of circulating factors, exerting central 
negative feedback control (Kennedy, 1953). Support for this theory came in 1972, when 
studies of genetically obese and diabetic mice confirmed the presence of such molecular 
factors (Johnson & Hirsch, 1972). In the 1980s researchers showed that adipose tissue 
secretes multiple factors affecting control over energy homeostasis, and whose 
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production is affected by metabolic dysregulation. These signaling molecules remained 
elusive until 1994, when Zhang et al. was able to sequence the obese gene and its protein 
product, leptin ( Zhang et al., 1994). Through the 1990s researchers confirmed the 
validity of Kennedy’s original hypothesis, along the way solidifying general acceptance 
of the adipose tissue as an endocrine organ, by identifying additional secretory factors, 
termed adipokines. By 2004 scientific community recognized over 75 distinct adipokines 
secreted by the adipocytes and as technology advanced this number grew (Trayhurn & 
Wood, 2004). Researchers have also discovered secretions of inflammatory cytokines 
from the non-adipose cells in the adipose tissue, the stromal vascular fraction (SVF). 
These include preadipocytes, endothelial cells, fibroblasts, mast cells, eosinophils, B 
cells, T cells and mature macrophages, among others. Even though many endocrine 
factors are not produced directly by the adipocytes, estimated 14 – 19% of adipose 
tissues’ cytokines originate in the SVF, as their expression and secretion is enriched by 
the paracrine signaling initiated by the adipose tissues itself (Peinado et al., 2012). In a 
positive feedback loop, SVF’s paracrine signals themselves exert control over the 
secretion of adipocyte-derived adipokines (Peinado et al., 2012). Of the vascular 
fraction’s leukocytes, macrophages are the most abundant cells, ranging from 10% in 
lean AT to almost 50% in obese AT (Weisberg et al., 2003). 
 In line with the complexity of these interactions Chaldakov and his colleagues, 
coined a new term to describe this intertwined concept – neuroadipology, tying together 
multiple sub-disciplines such as neuroendocrinology, neuroimmunology, 
neurogastroenterology with neurobiology (Chaldakov et al., 2010). One of the reasons 
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investigators have been kept at bay is the complexity of the necessary analysis and the 
difficulty in pinpointing with any certainty the origins of specific molecules (Pardo et al., 
2012). One of the earlier gene-expression profiling studies found that 40% of genes 
expressed in the adipose tissue were novel (Okamoto et al., 2006). A more current paper, 
profiled proteins released by the primary human adipocyte, counted 347 distinct proteins, 
44 of which are novel adipokines (Lehr et al., 2012). In the same paper scientists note 
that up to this point researchers have uncovered over 700 different, mostly distinct, 
secretory components potentially released by the adipose tissues (Lehr et al., 2012). This 
number is bound to grow as new and novel methods of measuring are invented, along 
with improvements in the analysis and the equipment sensitivities. 
 The factors discovered through adipoproteomic analysis fall into many categories, 
cytokines, chemokines, growth factors, enzymes, free fatty acids, steroid hormones, 
prostaglandins, endocannabinoids, extracellular matrix proteins, lipid droplet-associated 
proteins and anti-inflammatory lipid mediators such as resolvins, protectins, lipoxins and 
neuroprotectin D (Chaldakov et al., 2010). Much of the latest research has concentrated 
on a few key adipose tissue derived proteins implicated in obesity and chronic low-grade 
inflammation that leads to a variety of disease states. Particular attention has been paid to 
adiponectin, leptin, resistin, visfatin, interleukin 6 (IL-6), interleukin 10 (IL-10), 
monocyte chemoattractant protein 1 (MCP-1) and tumor necrosis factor alpha (TNF-α) 
(Halberg et al., 2008; Harwood Jr., 2012). These signaling and mediator molecules 
establish an auto-paracrine communication cross link between adipose tissues and the 
other organs and tissues, such as liver, skeletal muscles, central nervous system, 
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cardiovascular system and the pancreas. The cross-talk is bidirectional, as organ systems 
themselves release factors and cytokines that exert adipocentric influence. Certain 
cardiokines and myokines, from the heart and from the skeletal muscles, respectively, 
have been shown to interact with the adipose tissue itself (Rosen & Spiegelman, 2006; 
Romacho et al., 2014). While these mechanisms of action have not been clearly 
elucidated, there is a growing stream of evidence supporting the existence of these 
connections (Ouchi et al., 2011). 
 It is interesting to note that even in utero during fetal development the nascent 
adipose tissue exerts endocrine control over the development of many organ systems. A 
number of expressed factors have been noted to act in an endocrine manner, factors such 
as IL-1, -1A, -1B, -4, -5, -6, -8, -12, -15,  IGF-I (Insulin-like growth factor I), -II, leptin, 
IGFBP-1 (Insulin-like growth factor-binding protein 1), -2, -3, -4, -5, APO-E 
(Apolipoprotein E), APO-A1, APO-A2, APO-R1, TGB-beta, adipsin, BDNF (Brain-
derived neurotrophic factor) , TNF-α, adiponectin, ANG-2 (Angiopoietin-2), PAI-1 
(Plasminogen activator inhibitor-1) (Hausman et al., 2006).  During the postnatal and 
neonatal development, the list of secreted adipokines expands further (Hausman et al., 
2006; Poulos, Hausman, & Hausman, 2010) 
 During obesity, paralleling adipose tissue expansion, the secreted amounts of the 
above mentioned factors swell, simultaneously changing their profile. 
 
Lean Versus Obese Adipose Tissue. 
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 Another twist in the saga of food exerting hormone-like effects leading to 
inflammation is the changeover in the expressed factors based on the internal 
disturbances of the adipose tissue. Current consensus that adipose tissue can and does act 
in an endocrine capacity raises the question of the underlying mechanisms. What prompts 
the production and secretion of factors that lead to the state of inflammation? To address 
it, first we must look at the changes occurring in a healthy adipose tissue once the long 
term energy balance becomes positive. 
ATMs, M1 vs. M2 profile 
 
 In 2003, two seminal works published findings that obesity induces macrophage 
infiltration in adipose tissues of mice, as well as humans (Weisberg et al., 2003; Xu et al., 
2003). These studies shed light on the role of macrophage-induced inflammation 
component of diet induced obesity. Amongst the numerous types of macrophages, two 
subsets of the adipose tissue macrophages are believed to wield the most influence. In the 
obese AT, M1, also known as the classically activated, is the predominant phenotype, but 
in the lean adipose tissues, M2 or alternatively activated macrophages, is the principal 
phenotype (Lumeng et al., 2008). As will be detailed in the next paragraph, the principal 
differentiators between the two are the gene expression patterns, with M1 expressing 
proinflammatory factors, while M2 produces high levels of anti-inflammatory secretions. 
 Currently, there is considerable evidence indicating that both subtypes of ATMs 
exist synchronously, in the lean as well as in the obese AT, but in immensely different 
quantities (Lumeng et al., 2007; Prieur et al., 2011). Lean AT contains about 10% 
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resident macrophages in anti-inflammatory, M2 polarization (Osborn & Olefsky, 2012). 
During obesity macrophage number increases significantly, up to as much as 50-60% of 
adipose tissue stromal fraction, with over 90% of these ATMs becoming 
proinflammatory, M1 polarization (Osborn & Olefsky, 2012; Sorisky et al., 2013). Unlike 
M1 ATMs, large number of which is recruited into obese AT, M2 ATMs are evenly 
distributed in adipose tissue under both obese and non-obese conditions (Lumeng et al., 
2008). And as the expansion takes place, the influx of M1 polarized cells grows 
exponentially causing the inversion of M2/M1 ratio, shifting the non-inflammatory 
milieu maintained by M2 macrophages toward the pro-inflammatory state (Lumeng et al., 
2008; Prieur et al., 2011).  
 The M2 type macrophages exert anti-inflammatory effects and have been shown 
to be responsible for the tissue repair, remodeling and angiogenesis, increased insulin 
sensitivity, upregulation and expression of IL-10, IL-1 receptor antagonist and arginase-
1. The M2 ATMs have also been found to secrete catecholamines to induce 
thermogenesis in brown adipose tissue and lipolysis in white adipose tissue (Nguyen et 
al., 2011). To protect from metabolic deterioration during lipolysis, ATMs temper 
extracellular increase in free fatty acids, thereby protecting the primary function of the 
adipose tissues (Kosteli et al., 2010). As an organism becomes increasingly obese there is 
a shift to a more proinflammatory polarization, along with considerable inflow of M1 
macrophages into AT. M1 ATMs secrete TNF-α, CD11c, CCR2 (C-C chemokine 
receptor type 2), IL-6 and WNT5a (wingless-type MMTV integration site family, 
member 5A), produce inducible nitrix oxide synthase (iNOS) and reactive oxygen species 
28 
 
(ROS), cause insulin resistance and are generally thought to be responsible for inducing a 
number of inflammatory pathways leading to a state of chronic low-grade inflammation 
(Gordon, 2007; Galic et al., 2010; Ouchi et al., 2011; Johnson et al., 2012; Cao, 2014). 
 Despite their apparent importance in regulating adipose tissue inflammatory 
responses, the crucial mechanism responsible for switching from M2 to M1 polarization 
remains poorly understood. In 2007 Saltiel et al. put forth a model describing the 
polarization switch from M2 to M1 phenotype as AT transforms from lean to obese. 
Examining lean/obese mice, his team hypothesized and were able to prove through flow 
cytometry and gene expression analysis, that positive energy balance leads to AT growth 
and under these conditions there is increased production of monocyte chemoattractants, 
followed by recruitment of inflammatory type CCR2+ monocytes to AT, where they 
differentiate into M1 polarized ATMs (Lumeng et al., 2007). Almost 90% of M1 ATMs 
in the obese AT, originate from these recruited monocytes and are not converted from the 
resident M2 population in situ, as others have hypothesized ( Lumeng et al., 2008; Prieur 
et al., 2011). 
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Hyperplasia 
 
 As the positive energy balance becomes chronic, the calories are converted and 
stored in the adipocytes, which from a metabolic vantage point is the most favorable, 
harking back to the ‘thrifty genotype’ theory (Neel, 1962). Adipose tissue is able to grow 
via two mechanisms: hyperplasia - increase in the number of adipose cells, and 
hypertrophy - growth of the existing adipose cells in size. Hyperplasia or recruitment and 
differentiation of new fat cells, is less common in adults and usually stops during puberty 
(Drolet et al., 2007; Spalding et al., 2008; Virtue & Vidal-Puig, 2008; Gustafson et al., 
2009). Evidence suggests that both lean and obese adipose tissue is in a constant state of 
remodeling, where old and sick adipocytes die, while adipose progenitor cells 
differentiate to take their place (Spalding et al., 2008). While at its core this is the 
physiologic hyperplasia, the process does not increase the total number of adipocytes and 
as such does not increase adipose tissue’s total lipid buffering and storing capacity. The 
limited number of studies concerned with hyperplasia; either have not looked at or have 
not been able to determine whether the new adipocytes came from the already committed, 
or preprogrammed progenitor cells, or whether they are a newly differentiated adipose 
tissue derived stem cells. It has been a considerable challenge to pinpoint precisely the 
origins of preadipocytes as well, and while many believe that preadipocytes originate 
from the stromal vascular fraction (SVF) of adipose tissue, there are some who think that 
they originate from the circulating bone marrow progenitor cells (Majka et al., 2011). 
 When hyperplasia does occur, it leads to a state known as “healthy obese” or 
“obese but metabolically normal (OMN)” (Stefan et al., 2008; Unger & Scherer, 2010; 
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Samocha-Bonet et al., 2012). Depending on the varying published articles, obesity in 
adults ranges from 6% to 40%. Despite their increased BMI or high percent body fat, 
they seem to have a better long term prognosis, showing 30% to 50% lower risk for 
mortality and morbidity, then their “typically” obese counterparts (Stefan et al., 2008; 
Ortega et al., 2013). There is however a compelling study that disputes these findings, 
stating that once fitness is accounted for as a confounder, any type of obesity has an 
increased risk for all-cause mortality (Kuk & Ardern, 2009). The underlying assertion for 
the OMN subjects is that hyperplasia does not elicit the proinflammatory polarization of 
the ATMs and adipocytokines. Additional research is required as most studies 
concentrate on subjects with pronounced disease, thus there is sparse evidence 
concerning hyperplasia in healthy adults who are in the process of gaining weight, or in 
the OMN population. 
 One more thought-provoking point requires consideration when discussing 
hyperplasia studies in an animal model, where the efforts of many researchers are 
concentrated. Since hyperplasia takes place in the young, it is of great importance to 
consider the age of the animals. Trying to decipher the transition timing in the animal 
model from the “child” and the “teenage” stages into adulthood can be very challenging 
and skew the results, as one study has hinted at in its findings (Jo et al., 2009). 
Hypertrophy 
 
 Hypertrophy, or increasing size of the adipose cells, is a more prototypical type of 
obesity (Kai Sun, Kusminski, & Scherer, 2011). The concept of limited expandability of 
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subcutaneous adipose tissue (SAT), the main free fatty acids (FFA) storage compartment 
in a healthy organism, supports the theory of lipid storage overflow (Virtue & Vidal-
Puig, 2008; Tsatsoulis et al., 2013). When subcutaneous fat storage depots exhaust their 
capacity to store lipids and are unable to expand further, the incoming triglycerides are 
diverted into ectopic depositions in non-adipose organs, such as liver, heart, muscles and 
pancreas, collectively termed visceral adipose tissue (VAT), or ectopic fat (EF) (Virtue & 
Vidal-Puig, 2008). Visceral fat surrounds the inner organs in the abdominal cavity, but 
more poignantly it accumulates inside these organs altering their metabolic processing. 
This certainly agrees with the accumulating evidence concerning body fat distribution 
and its influence on disease and inflammation, with VAT being more important than 
SAT, in the etiology of metabolic syndrome, as well as other diseases like T2D, CVD and 
various cancers (Unger & Scherer, 2010; Sacks & Fain, 2011). There is even evidence to 
suggest that there are intrinsic cell-autonomous differences between VAT and SAT cells, 
possibly accounting for their divergent metabolic functions (Tran et al., 2008). In 1983 a 
group of Japanese scientists developed a method using CT scans for measuring and 
distinguishing fat deposits, and has since followed up with studies indicating that 
accumulation of VAT abets development of metabolic disorders (Matsuzawa et al., 
2011). More recently, with the development and advancement of new radiological 
techniques, similar findings have been confirmed by others (Bentham Science Publisher, 
2006; DeFronzo, 2010; Gastaldelli & Basta, 2010; Sacks & Fain, 2011; Sironi et al., 
2012; Snel et al., 2012). Many of the same studies see ectopic fat das a predictive marker 
of developing cardiovascular disease, insulin resistance and Type 2 Diabetes (Preis et al., 
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2010; Tadros et al., 2010; Morelli et al., 2013). A number of additional studies have 
linked increased ectopic fat to an increase in the mediastinal, as well as in the total fat 
(Sacks & Fain, 2011; Sironi et al., 2012; Morelli et al., 2013). 
 Of note is a 2013 study, contradicting the generally accepted pathological role of 
hypertrophic AT, reporting that in 55 obese patients undergoing bariatric surgery and 
omentectomy, the increase in major omentum was due largely to hyperplasia and not 
hypertrophy (Arner et al., 2013). The contradictory findings were based on regression 
analysis of cell samples taken from the patients and while the study seems to be pertinent, 
its limitations are crippling. The small sample size, inclusion of only nine obese men and 
zero lean subject of either sex, raise questions of clinical significance of these findings. 
More importantly this study failed to examine the life-cycle time frame at which omental 
adipose cells were extracted. This key metric would indicate whether these cells are being 
differentiated into mature adipocytes, therefore undergoing hyperplasia, to take place of 
the necrotic mature adipocytes that have gone past their physiologic expansion limit – the 
end point of hypertrophic growth. A similar study of women undergoing abdominal 
hysterectomy came to an inverse conclusion (Drolet et al., 2007). Authors looked at 
patients’ subcutaneous and omental AT to determine whether adipocytes expressed 
depot-specific transcription factors involved in lipid metabolism. They also considered 
gene expression patterns along with computed tomography body fat distribution and 
compartment specific adipose cell size. One of their main findings was a bit 
counterintuitive. Researchers discovered that hyperplasia is predominant in the 
subcutaneous fat cells (SAT), while hypertrophy was visible in both compartments, 
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omental and subcutaneous (SAT) (Drolet et al., 2007). It is relevant to mention the 
inclusion of obese and lean subjects in this study, which might better explain hyperplasia 
in SAT. 
Adipose Cell Growth 
 
 For years some scientists have argued that sustaining an appropriate amount of 
adipose tissue is crucial for optimal health (Wood et al., 2009). In light of this argument, 
a proper physiologic response to a chronic caloric abundance would be expansion of SAT 
that encompasses both, increase in the number of adipocytes as well as a minimal 
increase in their size. Conversely, a pathologic response leads to hypertrophy, without 
any meaningful increase in the total quantity of adipose cells. Some have suggested that 
the breakdown of the expansion process is a series of cycles of adipocyte hyperplasia, 
followed by hypertrophy and hypoplasia, leading to the general degradation of adipose 
tissue function, exhaustion of adipocyte progenitor pool, followed by impaired 
expandability of SAT (White & Tchoukalova, 2012). Gustafson et al. has stated that 
inappropriate signaling of progenitor cell’s differentiation pathways leads to hypertrophic 
expansion (Gustafson et al., 2013). However, as long as there is production of new 
adipocytes, lipid accumulation is controlled and the energy homeostasis is maintained. 
The ability to recruit new adipocytes therefore, prevents build-up of ectopic lipids, 
followed by inflammation and a switch to a pro-inflammatory milieu. As many studies 
have pointed out, expansion of AT during caloric surplus is instrumental in preventing 
inappropriate adipose cell enlargement (Blüher, 2009; Christine et al., 2009; White & 
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Tchoukalova, 2012). Some scientists even suggest that adipogenesis conveys organism 
wide protection and delays, rather than causes MS instigated by overnutrition (Christine 
et al., 2009; Unger & Scherer, 2010). 
 Understanding adipocyte life cycle becomes paramount, as the knowledge of this 
process offers a glimpse into the events that initiate AT inflammation. However, studying 
adipose cell turnover has been a considerable challenge. While generating new 
adipocytes from adult human mesenchymal stem cells and pre-adipocytes in vitro is 
possible, it was unclear, until very recently, if and how this happened in vivo (Cinti et al., 
2005). Using methods adapted to studying AT in animals, such as incorporation of 
labeled nucleotides, is not transferable to humans due to its possible toxicity. Performing 
multiple time-lapsed biopsies to examine cell proliferation in humans is unethical and 
overly invasive. Looking for molecular markers associated with AT cell division might 
give clues of mitotic activity, but cannot provide information regarding the fate of scions 
of that cell. These issues limit researchers’ ability to study cells that do not proliferate 
further or express mitotic markers themselves, for example, adipocytes or neurons. In 
2004 a novel approach for testing in vivo adipogenesis was developed, via incorporation 
of a stable isotope deuterium into adipocyte DNA (Deoxyribonucleic Acid) (Strawford et 
al., 2004). More recently scientists refined this approach making it more accurate by 
purifying the isolated adipocytes from other potential contaminants (White & 
Tchoukalova, 2012). Their approach shows results comparable with the only other in vivo 
adipocyte turnover measuring method. Which was developed by Spalding et al. via 
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incorporation of atmospheric 14C in adipocyte DNA, left over from the 1960s above 
ground nuclear bomb tests (Spalding et al., 2008). 
 As both of these studies agree, in an adult, there is a continuous turnover of 
adipocytes averaging about 10% per year of the total AT cell count (Spalding et al., 2008; 
Arner et al., 2010; White & Tchoukalova, 2012). Thus due to necrosis and apoptosis, the 
number of adipocytes is in a constant state of flux forcing continuous regeneration of new 
adipocytes. Obese individuals turnover larger quantity of these cells than their lean 
counterparts do, with the difference between the two population of ≈0.5 × 1010 cells, with 
an estimated half-life of an adipocyte of about 8.3 years (Spalding et al., 2008). In 
contrast to the bulk of the studies, Spalding et al. approached AT changes from a 
different angle, he considered changes during the weight loss stage and not during the 
weight gain. His team showed that adipocyte number is tightly controlled and not 
influenced by the energy balance.  They found no significant change in the number of 
adipocytes two years post bariatric surgery followed by an extreme caloric restriction 
diet, even though BMI and fat cell volume decreased (Spalding et al., 2008). Of interest 
are the findings from other research indicating that individuals with highly enlarged 
adipocytes have a lower cell turnover rate and that obese have fewer available 
preadipocytes (Tchoukalova et al., 2007; Arner et al., 2010). And yet another study 
confirms these assertions, reporting that in obesity there is a reduction in the number of 
adipose progenitor cells (Oñate et al., 2012). Collectively, evidence suggests that 
regardless of whether the adipose tissue is expanding or contracting the number of 
adipocytes is fairly constant. More importantly, these findings imply that at any given 
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time the quantity of AT cells lingering in the necrotic or apoptotic state is higher in obese 
individuals not only in absolute terms, but also in relative terms (on percentage basis). 
Simply stated this means that obese have a higher percentage of adipocytes in the 
proinflammatory state. Although scientists recognize that during obesity hypertrophy 
predominates, there is still some debate as to the role of hyperplasia and a possible 
cyclicality of the expanding AT. 
 As adipocytes grow past their physiologic limit, they become dysfunctional and 
are tagged for removal from AT, similar to a pathogen or any other dead cell. 
Macrophages are superbly suited for these tasks and have been shown to aggregate into 
crown-like structures (CLSs) around necrotic adipocytes (Tchoukalova et al., 2007; 
Osborn & Olefsky, 2012). While scientist speculated that adipocyte necrosis drives the 
inflammatory response, it turned out to be simply and association. A couple of recent 
studies argue that DIO induced adipocyte necrosis is an intrinsic cellular process, not 
triggered by ATM accumulation, which arrived in the inflamed regions prior to any 
detectable early stage adipocyte necrosis (Li et al., 2010; Feng et al., 2011). Both studies 
argue that adipocyte necrosis is disassociated from inflammation, but it is also possible 
that our current detection techniques are not of sufficient sensitivity. Henceforth, the 
question of whether inflammation triggers necrosis or necrosis initiates inflammation 
remains outstanding (Osborn & Olefsky, 2012).  
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Lipotoxicity 
 
 A healthy adipose organ can and does buffer daily lipid swings by controlling the 
postprandial serum concentration of non-esterified fatty acids (NEFA), the so called 
‘fatty acid flux’. Serum FFA and triglyceride levels are never constant, swinging up and 
down throughout the day. Adipose tissue’s ability to effectively buffer the upswings 
protects the lipid-intolerant organs from lipotoxic damage. Studies have shown that in 
obese individuals with dysfunctional adipose tissue, inability to appropriately take up 
lipids, leads to lipotoxicity which is an important pathogenic driver in etiology of 
metabolic syndrome and a switch over to a pro-inflammatory adipocytokine profile 
(Frayn, 2002; Schaffer, 2003; Unger, 2005; Virtue & Vidal-Puig, 2008; Unger & Scherer, 
2010; DeFronzo, 2010; Snel et al., 2012; Kusminski et al., 2009; Estadella et al., 2013). It 
has also been suggested that hypertrophic expansion reduces effectiveness of the AT 
storage capacity and as a consequence, fatty acids are redirected into EF storage (Sorisky 
et al., 2013). It is important to note that only when SAT’s ability to store and oxidize 
excess fatty acids is impaired and lipids spill over into EF, does the body succumbs to 
deleterious effects of overnutrition. Until such a point, expansion of adipose tissue is 
considered to be a protective mechanism, helping the organism cope with a positive 
energy balance (Kusminski et al., 2009; Unger & Scherer, 2010). Some even think that 
ectopic fat accumulation can be seen initially as a protective mechanism against 
lipotoxicity (Morelli et al., 2013). 
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Hypoxia 
 
 At the cellular level adipose tissue is heterogeneous, with adipocytes comprising 
60% of the total cell content, while the other 40% is made up of multitude of cells 
collectively known as SVF (Wood et al., 2009). Adipocytes are able to expand up to ≈20 
fold in diameter and several thousandfold in volume (Jernås et al., 2006). Generally, 
WAT is considered to be poorly vascularized and in 2002 scientists demonstrated that 
without angiogenesis adipose tissues are not able to expand (Rupnick et al., 2002; 
Virtanen et al., 2002; Kabon et al., 2004; Fleischmann et al., 2005). Such extreme 
volumetric expansion, even when accompanied by angiogenesis, creates areas devoid of 
blood supply. O2 diffusion distances have been measured at 100-200 µm, but in some 
cases O2 pressure may be close to zero at just 100 µm from the capillaries (Folkman et 
al., 2000; Gatenby & Gillies, 2004; Brahimi-Horn & Pouysségur, 2007). Thus large 
adipocytes, which can grow to be 150-200 µm in diameter (Skurk et al., 2007), exceed 
physical limitations of oxygen diffusion creating environments conducive to expression 
of inflammatory genes and altered adipokine expression (Gatenby & Gillies, 2004; 
Brahimi-Horn & Pouysségur, 2007; Wood et al., 2009; Trayhurn, 2013). Researchers 
have documented intriguing dichotomies between adipose tissues of obese and lean 
subject. In lean subjects blood flow to adipose tissue increases postprandially, but it does 
not change in the obese (Karpe et al., 2002; Kabon et al., 2004; Goossens et al., 2011). In 
obese the adipocyte size is increased in SAT relative to VAT, but there is no change in 
size in the lean subjects (O’Rourke et al., 2011). An important marker of tissue oxygen 
perfusion is the capillary density and the obese VAT and SAT had reduced density 
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compared to the lean VAT and SAT. Also, in obese adipose tissue, there is no difference 
in density between VAT and SAT, while the lean adipose tissue, shows greater capillary 
density in VAT than in SAT (Pasarica et al., 2008; O’Rourke et al., 2011; Spencer et al., 
2011). But the lower capillary density in obese adipose tissue coincides with larger 
vessels, indicating that the body is trying to deliver O2 to the undernourished adipocytes 
(O’Rourke et al., 2011; Spencer et al., 2011). 
 Besides blood flow and capillary density data, research shows direct evidence of 
hypoxia in the human adipose tissue (Virtanen et al., 2002). In a study of subjects during 
surgery, Po2 in the upper arm SAT was lower in the obese than in the lean patients 
(Kabon et al., 2004). Another study employing O2 electrode as a sensor, indicated lower 
Po2 in AT of overweight and obese versus lean patients (Pasarica et al., 2008). Moreover, 
there is an inverse relationship between percent body fat and Po2, along with increasing 
accumulation of ATMs as the O2 levels decline (Pasarica et al., 2008). There is additional 
evidence of existence of a direct dose-dependent relationship between O2 perfusion and 
several adipokines, both, in terms of gene expression and manufacture of mature proteins 
(Wood et al., 2011). Adipocytes appear to be very sensitive to the smallest changes in the 
oxygen pressure even within the normal physiologic range, constantly titrating their 
metabolic function (Trayhurn, 2013). Clinical studies support these findings, pointing out 
that hypertrophy spawns areas of local hypoxia at the earliest stages of expansion 
(Trayhurn & Wood, 2004; Fujisaka et al., 2013). Collectively, scientists suggest that 
many inflammatory factors are upregulated by hypoxia and the underlying 
interdependency of adipose tissue on O2 tension leads to an increase in ATM 
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accumulation, changeover in gene transcription, expression of proinflammatory proteins 
and recruitment of inflammatory factors. 
 From published studies it is evident that obese adipose tissues are infiltrated with 
M1 polarity macrophages and as Rausch et al. confirmed via flow cytometry and 
immunohistochemistry, hypoxic adipose tissue is colocalized with M1 polarity 
macrophages (Rausch et al., 2007). It has been thought for some time that hypoxia was 
partially responsible for the influx of proinflammatory macrophages, but only recently 
scientist illuminated the possible mechanism implicating hypoxia as the inducer of the 
changeover to the M1 polarity ATMs, possibly via HIF-1α (Hypoxia-inducible factor 1-
alpha) transcription factor (Fujisaka et al., 2013). But Fujisaka et al. observed and 
cautioned that while M1 ATMs became considerably more hypoxic than M2 ATMs, at 
least in SAT, hypoxia alone was not a sufficient driver of the increased influx of the M1 
ATMs (Fujisaka et al., 2013). Influx of ATMs may be an effect rather than the causation 
of inflammation in the hypoxic area, perhaps macrophages arrive to remove dead, 
necrotic, apoptotic adipocytes and/or scavenge for the already released lipid droplets, 
linking hypoxia to the organism’s survival as it struggles to intercede in hypertrophic 
expansion (Cinti et al., 2005; Wood et al., 2009; Miyake & Yamasaki, 2012). Realization 
that there is another, hypoxia-independent pathway, which also facilitates recruitment of 
M1 ATMs, presents significant challenges in deciphering the M1 engagement mechanism 
(Fujisaka et al., 2013). Indeed, leptin has been shown to be macrophage chemoattractant, 
along with MCP-1 (Curat et al., 2004; Lilja et al., 2012). It seems that triggers 
responsible for the recruitment of the macrophages remain an enigma. 
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 Hypoxic changes in AT lead to inflammation through multiple pathways. 
Hypoxia has been shown to inhibit differentiation of preadipocytes into adipocytes, 
controlled via the downregulation of the expression of the nuclear transcription factor 
PPARγ through hypoxic inducible factor (HIF)-1 (Yun et al., 2002; Kim et al., 2005; 
Zhou et al., 2005; Lin et al., 2006;Semenza, 2011; Shin et al., 2012). HIF is a master 
regulator of the cellular response to hypoxia, which has evolved over the millennia of 
evolution to expeditiously restore oxygen flow. The alpha subunit of the HIF-1 
heterodimer is thought to be the molecular O2 sensor (Semenza, 1998; Poitz et al., 2014). 
It is stabilized by the low oxygen pressure, allowing the binding of HIF-1 transcription 
factor to its domain, inducing transcription of over seventy genes. These genes are 
involved in inflammation, angiogenesis, apoptosis, cellular stress and glucose metabolism 
amongst other processes (Semenza, 2003; Sun et al., 2013). It has also been noted that in 
mature adipocytes expression of PPARγ is diminished as well (Hosogai et al., 2007; El-
Gilany & Hammad, 2010) Reduction in the expression of PPARγ and inability to 
differentiate new adipocytes in a hypoxic environment could be an effective mechanism 
to control the runaway growth of the adipose tissue, and is consistent with the earlier 
described theory supporting the concept that the number of adipocytes stays nearly 
constant in the adulthood (Spalding et al., 2008; Virtue & Vidal-Puig, 2008; Gustafson et 
al., 2009). NF-kβ, another pertinent transcription factor is also affected by the low 
oxygen tension. NF-kβ has been shown to mediate inflammatory signaling pathways 
associated with TNF-α and HIF-1a, and is thought to be attempting to inhibit apoptosis to 
allow the cell to survive the perceived intermittent hypoxic stress (Rius et al., 2008; 
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Taylor, 2008). Furthermore, hypoxia induces activation of NF-kβ inside macrophages 
(Rius et al., 2008). Preadipocytes themselves are known to secrete multiple inflammatory 
adipokines, leptin however, not being one of them, but in the hypoxic environment 
preadipocytes have been shown to switch on leptin production ( Wang et al., 2008). 
Quantitatively, produced leptin does not significantly raise circulating levels of the 
hormone, it does however, play a local paracrine role recruiting macrophages along with 
other inflammatory factors to the locally hypoxic adipose tissue. 
 As previously indicated, a large portion of the adipose tissue is comprised of the 
stromal vascular fraction (SVF) and a low Po2 has been shown to induce secretion of 
crucial cytokines and chemokines from these cells. Factors such as IL-6, IL-1β, MIF-1, 
TNF-α, CCL-2 (MCP-1), MMP2 (matrix metallopeptidase 2), MMP9, Angptl4 
(Angiopoietin-like 4), PAI-1, leptin, as well as GLUT1, PERK (phosphorylation by the 
endoplasmic reticulum kinase) and c-JUN transcription factors flood the area or are 
produced in the hypoxic adipose tissues (Wood et al., 2009; O’Rourke et al., 2011; Pérez 
et al., 2010). M1 macrophages themselves have been shown to express proinflammatory 
genes, including, Tnf, Il6, Il1b and Nos2 (Fujisaka et al., 2013). Although some of the 
infiltrating cytokines and transcription factors are anti-inflammatory, such as IL-10, NF-
kβ, macrophage migration inhibitory factor (MIF), they are unable to cope and ultimately 
loose the battle of the inflamed and expanding adipose tissue. A number of angiogenic 
factors are also upregulated during hypoxia, such as VEGF (Vascular endothelial growth 
factor), leptin and apelin, in a classical response to the low oxygen tension, in an attempt 
to restore blood flow through capillary network growth (Trayhurn, 2013). But just like 
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the anti-inflammatory stimuli, the angiogenic catalysts are no match for the expanding 
adipose tissue. 
 
Obesity, Inflammation and an Impaired Immunity 
 
 Clearly there is merit in the argument that in order to survive organisms depend 
on two key processes, storing energy and fighting infections. Ostensibly the molecular 
and cellular pathways seem to be unrelated - AT being charged with energy stores, while 
infections are the domain of the immune system. At its core the connections remain 
elusive, but the association is likely attributable to the way AT influences immunologic 
functions. In all likelihood, these poorly understood connections work in concert and as 
the research progresses, a new term - immunometabolism, has been coined to describe 
the intersection of two seemingly different disciplines of immunology and metabolism 
(Mathis & Shoelson, 2011; Schipper et al., 2012). 
 DIO forces a change in the AT-resident immune cells phenotype and numbers 
(O’Rourke et al., 2011). Obesity itself provides danger signals and bacterial activators 
that trigger inflammatory cascades and prompt the ATM polarization switch, triggering 
adipose tissue inflammation. Moreover, there is a reduction in AT-resident regulatory T 
cells and the IL-4 producing eosinophils, while inflammatory cell such as IFN-y+ Th1 
cells and CD8+ T cells proliferate and multiply. These changes lead to an archetypal Th1 
inflammatory response, but in DIO instance it results in a long term low-grade 
inflammation and insulin resistance. As countless epidemiologic studies indicate, AT 
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inflammation and insulin resistance underlie a large portion of comorbidities in the obese 
population. As obesity triggers chronic low grade inflammation, it alters the overall 
immune system homeostasis. Comparing lean and obese subjects Nieman et al. noticed 
multiple discrepancies in leukocyte numbers, subset counts, phagocytic and oxidative 
burst activity of monocytes, as well as impaired lymphocyte proliferation to polyclonal 
stimulation (Nieman et al., 1999). In obese versus their lean counterparts, circulating 
mononuclear cells display a pro-inflammatory polarization (Ghanim et al., 2004). Obesity 
has also been implicated in advancing thymic aging and reducing T-cell variability, 
apparently harming immune system’s surveillance capabilities (Yang et al., 2009). 
Impaired immune cell activation is a common mark of Type 2 diabetes, a prevailing 
complication following onset of obesity (Geerlings & Hoepelman, 1999). Farooqi and his 
colleagues have noted, that individuals with genetic mutations that impede bodies leptin 
synthesizing abilities, become morbidly obese and present weakened immune defenses 
(Farooqi et al., 2002). These are but a few examples of the far reaching consequences of 
obesity. The mechanisms responsible for the altered immune state are multifactorial, but 
the key to understanding inflammation-disease link is in understanding how the energy 
rich environment of DIO impacts immune cell function. 
Innate Immunity 
 
 Innate immunity is a set of predetermined humoral and cellular factors that have 
developed to sense physiologic abnormalities, trigger responses and bring the whole 
system back into equilibrium. Interestingly the immune responses are triggered not only 
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by the exogenous, but endogenous stimuli as well. Microbes, viruses and bacteria are the 
typical stressors of the immune system, warranting a rather acute inflammatory response. 
But beyond the initial reaction, innate immune system is tasked with resolving 
inflammation, repairing damaged tissues and activating adaptive immune system to 
prepare memory for future confrontations. The difficulty in teasing out individual 
relationships to attribute causation of various responses lies in their overlapping nature. 
For example, post workout repair of damaged skeletal muscles is intimately linked to 
circulating monocytes that induce myogenesis (Arnold et al., 2007). Monocytes patrol 
blood vessels and rapidly magnify the inflammatory response in case of damage or 
infection, followed by induction of an innate immune response (Auffray et al., 2007). 
Another example of such duality is liver X receptors (LXRs), that control inflammation 
as well as lipid metabolism (Hong et al., 2011). This control mechanism might be related 
to the high energy demands of the immune cells while generating reactive oxygen 
species, executing phagocytosis, directing cell migration and producing inflammatory 
cytokines. Interestingly, certain hormones that are dysregulated in DIO impair leukocyte 
function and leptin receptor (Mancuso et al., 2004; Baumgartl et al., 2006). The list of 
such examples is extensive, but I will focus on effectors of innate immunity in the context 
of DIO. 
 For many years scientists have known that DIO is marked by a state of chronic 
low-grade inflammation (Yudkin et al., 1999; Festa et al., 2001; Bulló et al., 2003; 
Engström et al., 2003; Yudkin, 2003; Fenton et al., 2009; Symonds et al., 2009; Maury 
&Brichard, 2010; Esser et al., 2014). Intrinsic inflammation is a normal physiologic 
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response to tissue expansion (Kosteli et al., 2010). Why that might be becomes clearer 
upon examination of the immune cells that are collocated with adipocytes within the AT, 
and are either summoned or secreted by the AT. An abundance of evidence points to a 
considerable number of key metabolic regulators that also play crucial roles in 
modulating inflammation (Lumeng, 2013). Moreover, adipocytes express receptors for 
microbial ligands, factors released upon tissue damage, inflammatory factors and the so-
called danger signals (Schäffler & Schölmerich, 2010). In obesity numerous molecular 
sensors are primed to react to exogenous factors. These inflammatory pathways are 
established to guard against infections and are the backbone of the innate immunity’s 
ability to sense these dangers. Unique chemical structures present in bacterial complexes 
(e.g. peptidoglycan, LPS, endotoxins), collectively termed pathogen-associated molecular 
patterns (PAMPs), also include peptides, proteins, carbohydrates, lipoproteins and 
nucleic acid species (e.g. CpG-DNA, dsRNA) (Zhang & Mosser, 2008; Kumar et al., 
2011). These PAMPs are identified by a set of mammalian pattern recognizing receptors 
(PRRs) that are triggered during the inflammatory response to DIO. PRRs are typically 
grouped into receptor classes: Toll-like receptors (TLRs), Nod-like receptors (NLRs), C-
type lectin receptors (CLRs), and Rig-1-like receptors (RLRs). Evidence suggests that 
TLRs, NLRs, and CLRs partake in DIO inflammation. 
Receptors 
 
 Free fatty acids have the ability to activate many TLRs, which in turn activate 
NF-kβ and production of ceramide along with its anti-inflammatory effects (Holland et 
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al., 2011). TLR4 plays a large role in sepsis and has the ability to activate virtually every 
type of leukocyte. Experimental evidence suggests that TLR4s are linked to obesity via 
increase in circulating LPS. The source of these LPS is gut microbiota, which responds 
quickly to dietary inputs and shortly after a high fat meal are capable of releasing enough 
LPSs to activate monocytes and endothelial cells (Manco et al., 2010; Rabot et al., 2010; 
Tilg & Kaser, 2011). Studies of obese mice show abnormally high levels of LPS 
translocating from the gut, resulting in increased circulating levels of LPS (Cani et al., 
2007). Additional studies have pointed out that TLR4 knockout mice are virtually 
immune to insulin resistance during a high fat diet (Davis et al., 2008). TLR4 expressed 
on adipocytes and hepatocytes are capable of modifying insulin sensitivity via MyD88 
(myeloid differentiation primary response gene) dependent pathway, while TLR4 on 
skeletal muscle fibers can regulate substrate utilization (Davis et al., 2009; Raetzsch et 
al., 2009; Frisard et al., 2010). A study of obese humans indicated that levels of LPS 
correlate with AT inflammation and insulin resistance (Saberi et al., 2009). 
 TLR2s are also capable of sensing dietary fatty acids and are activated by 
saturated, but not polyunsaturated fatty acids (Lee et al., 2004). Studies dealing with a 
loss of TLR2 function in murine models of obesity, show protection from DIO-activated 
insulin resistance (Ehses et al., 2010; Himes & Smith, 2010; Davis et al., 2011). 
Additional benefits of a TLR2 knockout model is a decrease in ATM accumulation and a 
decrease in pro-inflammatory cytokine production within adipose tissue ( Lumeng, 2013). 
 Besides reconnaissance of extracellular threats there is constant surveillance of 
the cytoplasm for danger signals, this job falls to Nod-like receptor’s (NLR). In 
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partnership with other PRRs, NLRs are activated by various pathogens (e.g. Bacterial 
toxins, viral RNA, fungal glycoproteins) and other immune activators (asbestos, 
amyloid β) (Davis et al., 2011). There is evidence to indicate that the NLR functionality 
overlaps with obesity and is activated to negatively influence insulin resistance (Lumeng, 
2013). NLRP3 forms a structure known as an inflammasome and is activated to translate 
danger signals into the production of proinflammatory cytokines (IL-1β, IL-18) via 
Caspase-1 (Wen et al., 2012; Lumeng, 2013). This mechanism is especially active in 
macrophages playing a leading role in gut inflammation and infectious responses (Davis 
et al., 2011). Additional research indicates that NLRP3 might be an activator of NF-kβ 
signaling, play an indirect role in leukocyte inflammation and apoptosis, gout, Type2 
diabetes and neuroinflammation during Alzheimer’s disease (Haneklaus et al., 2013; 
Heneka et al., 2013; Lumeng, 2013). In DIO inflammasomes are activated by ceramides, 
saturated fatty acids and ROS, thereby adversely impacting insulin receptor signaling 
(Lukens et al., 2011; Wen et al., 2011). Of interest are the NLRP3 knockout mice, as they 
have diminished markers of visceral fat activated M1 ATMs and a surge in anti-
inflammatory M2 ATM gene expression, suggesting inflammasomes’ involvement in 
ATM regulation (Lumeng, 2013). 
 Dendritic cells and macrophages are antigen presenting cells that express C-type 
lectin receptors (CLRs). Together with TLR activation signals, CLRs mediate antigen 
internalization, processing and surface presentation to improve T cells activation. Over a 
1000 various CLR extracellular domains, combined with a large variety of intracellular 
signaling domains have been uncovered. This multitude of combinations of 
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intra/extracellular domains result in antigen-receptor binding that drives immune system 
activation, while at other times allows inhibition of inflammatory signals (Lumeng, 
2013). Extensive studies have been conducted on a CLR termed oxidized low-density 
lipoprotein receptor 1 (LOX-1 or OLR1) found on endothelial cells, macrophages, 
platelets, and smooth muscle cells and which is partly responsible for endocytosis of 
oxidized LDL (Li & Mehta, 2000). LOX-1 is expressed ubiquitously in adipose tissues 
and atherosclerotic lesions where it induces macrophage and endothelial cell activation 
via NF-kβ and MAP kinase pathways (Li & Mehta, 2000). Elevated LOX-1 expression 
has been noted in obese rodent models as well as in obese humans, leading to extensive 
vascular inflammation (Inoue et al., 2005). High levels of AT LOX-1 parallel BMI and 
degree of insulin resistance (Brinkley et al., 2008; Kelly et al., 2008; Rasouli et al., 2009). 
LOX-1 acts as a metabolic switch mediating onset of inflammation in DIO. 
 Widely expressed TNF-a receptors and Toll-like receptors (TLRs) by adipocytes, 
underscore the bidirectionality of the immunometabolic cross-talk (Cawthorn & Sethi, 
2008). Previously discussed concept of AT lipid spillover activates a multitude of ATM 
mediated inflammatory cascades via TLRs, ER-stress mediators and NLRP3 
inflammasome-mediated pathways (Erbay et al., 2009; Vandanmagsar et al., 2011; Wen 
et al., 2012). Lilja et al. noted that inflammation and adipogenesis are closely associated 
processes, with adipocytes and inflammatory cells sharing receptors and secreting pro-
inflammatory factors such as TNF-a, IL-1β, MCP-1 and TGF-β (Lilja et al., 2012). 
Authors hypothesized and subsequently elucidated how inflammation appears 
fundamental to the process of neo-adipogenesis, via the macrophage-derived MCP-1 
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protein and recruitment of bone-marrow derived progenitors along with TNF-a, LCN-2 
(Lipocalin-2) and IL-1β (Lilja et al., 2012). Additional evidence indicates that adipocyte 
precursor cells and macrophages share similar functions (Cousin et al., 1999; Charrière et 
al., 2003). Furthermore, adipokines and cytokines secreted by the ATMs are involved in 
the three crucial steps of AT growth and stability: adipogenesis, angiogenesis, and matrix 
and scaffold remodeling (Lilja et al., 2012). Preadipocytes were also shown to secrete 
MCP-1 and MIP-1a, factors known to be released by macrophages (Menghini et al., 
2005). 
White Blood Cells 
 
 Numerous systemic signals and dynamic cellular events drive obesogenic 
changes. In addition to the above implicated receptors, a number of innate immune 
cellular effectors play an important role in the inflammation during obesity. From our 
previous discussion it is clear that, macrophages are involved in multiple innate immune 
system initiations of responses to inflammation, and its resolution. Robbins et al. showed 
that inflammatory monocytes, Ly-6chi in mice and CD16+ in humans, generate pro-
inflammatory macrophages (Robbins & Swirski, 2010). It has also been noted that 
obesity increases circulating inflammatory monocytes in mice (Tsou et al., 2007). In 
obese human diabetic patients CD16+ monocytes are increased, but they decline 
coincidentally with surgical weight loss and improvements in vascular inflammation 
(Poitou et al., 2011). These findings promote the theory that bone marrow and splenic 
derived monocyte pools are ultimately responsible for the circulating inflammatory 
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monocytes that drive inflammation during obesity. The exact process of the ATMs 
changing polarization from the anti-inflammatory M2 to inflammatory M1 profile 
remains unclear, but monocyte recruitment concurrent with inflammatory signaling are 
clearly important factors (Weisberg et al., 2006; Westcott et al., 2009). 
 NK cells are lymphocytes derived from common lymphoid progenitor, along with 
B and T cells. There is research to suggest that during human obesity AT NK cells are a 
considerable source of inflammatory cytokines such as IFNy and can proliferate in 
omental fat along with obesity (O’Rourke et al., 2011). 
 Natural killer T (NKT) cells are a group of T cells that express markers of NK 
cells. Interest in NKT cells was piqued because of their ability to recognize lipids and 
glycolipids presented by CD1d receptor on antigen presenting cells, rather than peptide-
MHC (major histocompatibility) complexes. Link to metabolism comes from the fact that 
human omental fat contains large numbers of NKT cells along with CD1d+ cells (Lynch 
et al., 2009). Upon activation these NKT cells produce Th1 (IFNy), Th2 (IL-4) factors 
and decrease in number with DIO (Lumeng, 2013). Even though the exact mechanism in 
still unknown, the NKT cells are inhibited in the liver with the progression of DIO (Syn 
et al., 2010; Mantell et al., 2011). Ohmura et al. noted that despite gaining the same 
amount of weight, NKT cells deficient mice are protected from insulin resistance with 
DIO and exhibit reduction in ATM infiltration (Ohmura et al., 2010). 
 Recent evidence suggests that inflamed adipose tissue is being invaded not only 
by proinflammatory ATMs but also by T cells, neutrophils, natural killer cells and 
dendritic cells brought about by AT secretion of adipokines and chemokines (J. Liu et al., 
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2009; Moro et al., 2010; Nishimura et al., 2009). Wu et al. has shown that in DIO mice, 
AT is not only infiltrated by T cells, but there was also an increase in the expression of T-
cell chemoattractant RANTES (Wu et al., 2007). Another recent study shows that in 
mice, AT is exhibiting specific TCR rearrangements, indicating that clonal T cell 
populations are entering AT (Lumeng et al., 2009). This indicates that antigens in adipose 
tissue might be communicating with components of the adaptive immunity. TCR changes 
along with the extensive Type 1 ATM infiltration and Th1 cytokine secretion result in 
subsequent insulin resistance in AT and chronic DIO inflammation (Lumeng et al., 
2009). As mentioned previously, the current scientific consensus states that Type 1, 
proinflammatory ATMs are the driving force behind inflammation during DIO. An 
intriguing study by Nishimura et al. challenges this assertion. His team looked at the way 
T cell populations change with increasing obesity. They noted an increase in the ratio of 
CD8+ to CD4+ T cells in adipose tissue, weeks prior to the typical onset of macrophage 
infiltration (Nishimura et al., 2009). Additional research by two different scientific 
groups came to the same conclusion, although looking at different parts of this transition 
(Feuerer et al., 2009; Winer et al., 2009). Nishimura and his colleagues showed that in a 
DIO model of obesity, number of CD8+ effector T cells infiltrating epididymal adipose 
tissue increased, but the number of CD4+ helper and Treg cells declined (Nishimura et 
al., 2009). They were also able to show that the declining population of CD8+ T cells 
lowered ATM infiltration and AT inflammation, as well as alleviate systemic insulin 
resistance (Nishimura et al., 2009).Their research points to the possibility that CD8+ T 
cells and adipocytes cooperate in recruitment of ATMs to the adipose tissue. On the 
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whole these data suggests that obesity alters properties of the adipose tissue T cells prior 
to the arrival of the macrophages, but more importantly, that CD8+ T cells play an 
essential role in initiation and propagation of the AT inflammatory processes.  
 The importance of mast cells in the context of obesity became evident when Liu 
et al. studied mast cell deficient mice. HFD (high fat diet) induced obesity curtailed 
angiogenesis, but this had no impact on these mice most likely due to the mast cell 
induced expression of IL-6 and IFNy (Liu et al., 2009). 
 Eosinophils in partnership with mast cells react to increases in IgE and control 
mechanisms of allergic inflammation. Surprisingly these cells have been found in AT and 
are thought to regulate metabolism. Eotaxin, a potent eosinophil chemoattractants, is 
elevated in AT and serum of obese humans and animals, suggesting an inflammatory 
activation of allergic innate immune responses in DIO (Vasudevan et al., 2006; Lumeng, 
2013). Eosinophils which are present in AT decline with DIO and eosinophils deficient 
mice exhibit weight gain, as well as dampened insulin response, pointing to their 
protective role during the progression of obesity. This is thought to work via eosinophils 
secretion of IL-4 and IL-13, helping maintain alternatively activated ATM M2 
polarization (Wu et al., 2011). 
 Typical innate immune responses are marked by an early neutrophils infiltration 
of inflamed tissues (Mantovani et al., 2011; Schipper et al., 2012). Neutrophils are able to 
communicate with multiple components of both innate and adaptive immunity and are 
linked to macrophage immune function (Gordy et al., 2011). There is a link between 
neutrophils and obesity, their counts are associated with BMI, waist circumference and 
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total AT in female teenagers (Kim & Park, 2008). Elgazar-Carmon et al. showed that 
during a short period of HFD, large numbers of neutrophils move into the fat tissues 
(Elgazar-Carmon et al., 2008). Elgazar-Carmonet al. suggest systemic neutrophils 
activation in obesity and short-term infiltration of AT, at the onset of inflammation 
during DIO (Elgazar-Carmon et al., 2008). 
Humoral factors 
 
 Collaborating with the cellular components of the innate immunity are humoral 
factors, a number of which play a large role during inflammation. These include 
cytokines and chemokines, including innate inflammatory molecules such as C-reactive 
protein (CRP), defensins and complement components. Inflammatory cytokines amplify 
immune response and trigger leukocyte activation. In DIO most of these cytokines may 
emanate from the AT, largely from the stromal vascular fraction cells within AT, and are 
coupled with the AT growth and expansion. Complement system is another humoral 
component of the immune system, consisting of many different proteins that work 
together to “assist”, or complement, the antibody activity. Muscari et al. showed that core 
complement components C2, C3 and C4 are elevated in obese subjects, especially in AT 
(Muscari et al., 2007). The association is exceptionally strong for serum C3 levels with 
measures of insulin resistance, demonstrating yet another link between obesity and 
disease (van Greevenbroek et al., 2011). As far back as 1995 Muscari et al. showed 
association between complement and cardiovascular disease (Muscari et al., 1995). Later 
on, Bhatia and colleagues, using animal models demonstrated that the classical 
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complement pathway which is important in atherogenesis, is tied to protection from 
atherosclerotic plaque formation (Bhatia et al., 2007). It has also been known that platelet 
activation leads to activation and propagation of the complement system. Anfossi et al. 
has described causes of platelet dysfunction in central obesity, leading to increased risks 
of major cardiovascular events (Anfossi et al.i, 2009). Various genome-wide studies 
support the role complement system plays in obesity. Schadt et al. discovered that C3a 
receptor (C3a1) regulates visceral fat mass in mice (Schadt et al., 2005). Mamane et al. 
later showed that during obesity, C3a1 knockout mice are protected from insulin 
resistance and DIO caused inflammation (Mamane et al., 2009). It is thought that C3a1 
knockout mice are able to suppress ATM infiltration of adipose tissue and show a direct 
link between complement and pro-inflammatory ATMs. 
 Of interest is research that indicates that adipocytes are very similar to immune 
cells (T cells, macrophages, dendritic cells, etc.) in several features such as phagocytic 
properties, complement activation, and production of inflammatory mediators to 
pathogen sensing (Dixit, 2008; MacLaren et al., 2008; Neda Rasouli & Kern, 2008; 
Procaccini et al., 2013). 
Interleukin-17A 
 
 Adipose cells and innate immunity are part of an intricate network, in which 
during DIO, the chronic low-degree inflammatory state is able to affect acute 
inflammation (Galgani & Matarese, 2010). The implicated culprit of this link is IL-17A, 
it is produced in especially high amounts by activated CD4+ and CD8+ T cells and has 
56 
 
been found in eosinophils, neutrophils, and human blood monocytes (Kolls & Lindén, 
2004). It is a well-known inflammatory cytokine able to induce secretion of chemokines, 
growth factors (GM-CSF, IL-6), and adhesion molecules (ICAM-1) leading to 
accumulation, activation and migration of neutrophils and monocytes to the inflammatory 
site (Kolls & Lindén, 2004). IL-17A links adaptive and natural immune responses 
allowing T cells to control inflammatory responses induced by innate immunity (Galgani 
& Matarese, 2010). Pini and Fantuzzi et al. showed that in obese mice, during an induced 
peritonitis, a common model of acute inflammation, neutrophils produced high amounts 
of this cytokine (Pini & Fantuzzi, 2010). They noted significant increase in IL-17A 
mRNA expression in AT of obese mice versus their lean controls. But there was no 
increase of IL-17A production in spleen cells or in CD4+ T cells in the peritoneal fluid. 
Results of their study indicate that in their mouse model, obesity enhanced production of 
IL-17A (Pini & Fantuzzi, 2010). The deeper implication that requires further exploration 
is the possibility that AT induced Th 17-like response may be able to induce the break of 
self-tolerance in some conditions activating autoimmunity. A link between IL-17A, 
NLRP3 inflammasome, development of airway hyperreactivity (AHR), a key asthma 
feature, and obesity has been established by Kim et al. In a study of DIO mice scientists 
showed development of AHR dependent on IL-17A produced by ILC3 lymphoid cells 
and NLRP3 inflammasome (Kim et al., 2014). Ever present during obesity pro-
inflammatory ATMs induced production of IL-1β which expanded the number of ILC3 
cells. Authors hypothesized that since ILC3 cells are typically found in the 
bronchoalveolar lavage fluid of people suffering from asthma, DIO-associated asthma is 
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advanced by inflammation mediated via NLRP3, IL-1B and ILC3 cells producing IL-17A 
cytokine (Kim et al., 2014). 
Hormones 
 
 So far emphasis has been on cellular gateways and immune system factors that 
affect, or are affected by obesity-induced inflammation. Another distinct class of factors 
intertwined in this system is hormones, which have had an enormous body of research 
dedicated to the discussion of their roles in obesity, inflammation and disease. With 
leptin and adiponectin taking central role, these two have been mentioned in nearly every 
DIO related scientific paper to date. In the context of this thesis their role in modulation 
of inflammation and immune system control will be discussed. 
 Although leptin is produced by many cell types (e.g. stomach, skeletal muscles, 
bone marrow, placenta), it is primarily made by the white adipose tissue and its levels 
directly correlate with body fat mass and adipocyte size (Friedman & Halaas, 1998; Cava 
& Matarese, 2004). It is often referred to as a “satiety hormone”, as it controls body mass, 
specifically fat stores, and energy expenditures, exercising control over hypothalamic 
arcuate nucleus, midbrain and brainstem neurons. Leptin functions chiefly via a long arc, 
not impacting immediate meals, but rather balancing the ratio of total food consumed 
relative to the amount of expanded energy (Friedman & Halaas, 1998). Genetic 
abnormalities resulting in impaired leptin or its receptor production cause excessive food 
intake, weight gain and general obese phenotype (Chua et al., 1996). Initially these 
observations lead to the conclusion that leptin should abrogate DIO changes as it might 
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slow down fat storage. But the leptin paradox, also known as leptin resistance, has forced 
scientists to question its role, as observational studies have shown that most individuals 
with DIO have high levels of circulating leptin. Insert 218 Fig 2. 
 Adiponectin is mainly produced by mature adipocytes in WAT, but is also found 
in skeletal muscles, cardiac myocytes and endothelial cells. It has two distinct forms that 
act in different locals in the body (skeletal muscles and liver). Adiponectin is considered 
an anti-inflammatory, anti-apoptotic agent with pro-angiogenic properties and its levels 
inversely correlate with insulin resistance, weight gain and visceral obesity (Maeda et al., 
2002; Kusminski & Scherer, 2009; Shetty et al., 2009). Adiponectin’s receptors are 
expressed on most human monocytes, a large number of B cells and NK cells, but only 
on a small percentage of T cells (Pang & Narendran, 2008). Even though surface receptor 
expression is limited, new research indicates that adiponectin may be a negative regulator 
of T cells (Wilk et al., 2011). Adiponectin predominantly acts to counteract leptin’s 
influence and exerts control over the liver, its specific target organ (Yamauchi et al., 
2003). In skeletal muscles it stimulates fatty acids oxidation and glucose uptake. It is also 
capable of helping ameliorate insulin resistance, by enhancing insulin signaling and 
increasing glucose uptake in myocytes via induction of expression of GLUT-4 transporter 
(Ceddia et al., 2005). 
Hormones as cytokines 
 
 Leptin, adiponectin and other adipocytokines not only function as hormones 
controlling energy homeostasis and regulating neuroendocrine functions, but also act as 
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cytokines, are capable of modulating immune functions and inflammatory processes 
(Procaccini et al., 2012; Procaccini et al., 2013). Leptin modulates a number of pivotal 
pro-inflammatory processes; (i) it stimulates innate immune responses, prompts the 
production of key inflammatory factors (e.g. IL-1, IL-6, IL-12, TNF), (ii) it is able to 
activate neutrophils chemotaxis, (iii) it stimulates production of reactive oxygen species 
(ROS), and (iv) it promotes activation and phagocytosis by monocytes/macrophages and 
their production of leukotriene B4 (LTB4), cyclooxygenase 2 (COX-2) and nitric oxide 
(NO) (Carbone et al., 2012). In the innate immune system specifically, leptin activates 
NK cells, promoting NK-cell cytotoxicity through activation of signal transducer and 
activator of transcription 3 (STAT3) and IL-2 (Zhao et al., 2003). In comparison, 
adiponectin acts mainly as an anti-inflammatory agent. Studies show adiponectin 
inhibiting NF-kβ activation, leading to anti-inflammatory effects on endothelial cells 
(Ouchi et al., 1999). It also inhibits TNF-induced vascular cell adhesion molecule-1 
(VCAM-1) expression, endothelial-leukocyte adhesion molecule-1 (E-selectin), as well 
as the expression of intracellular adhesion molecule-1 (ICAM-1) (Ouchi & Walsh, 2007). 
In human monocytes, macrophages and dendritic cells, it induces secretion of anti-
inflammatory cytokines, such as IL-10 and a receptor antagonist IL-1RA, and inhibits 
production of INF-y (Wolf et al., 2004). 
Hormones and Adaptive Immunity 
 
 Both hormones and cytokines partake in the modulation of the adaptive 
immunity; leptin however, has more research elucidating its effects. In human adaptive 
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immunity leptin has been shown to promote proliferation and secretion of IL-2 from 
naive T cells (CD45RA+). Lord et al. in a study of ob/ob mice, noted that leptin 
deficiency is associated with immunosuppression and thymic atrophy, both actions of the 
adaptive immunity (Lord et al., 1998). Leptin also acts as a negative signal in the 
regulation of the expansion of the human regulatory T cells (Treg), specifically, naturally 
occurring Foxp3+CD4+CD25high cells, which are involved in the prevention of 
autoimmune diseases (De Rosa et al., 2007). In the same study De Rosa and colleagues 
noted that human Treg cells produce leptin and express large quantity of leptin receptor. 
Procaccini et al. noted that leptin, via activation of mTOR (mechanistic target of 
rapamycin), inhibits rapamycin-induced proliferation of Tregs (De Rosa et al., 2007). It 
was further noted by Kim et al. that mTOR kinase regulates varying aspects of helper T 
cell differentiation (Kim et al., 2002). Cumulative research on the leptin-mTOR axis 
suggests that this pathway might control immune system tolerance via cellular energy 
status and metabolic signaling in Treg cells (Carbone et al., 2012). As has been already 
mentioned, adiponectin is thought to be a negative T cell and NK cell regulator. In an 
additional study by Kim et al. adiponectin was found to suppress IL-2-enhanced 
cytotoxic activity of NK cells (Kim et al., 2006). Tsang and colleagues showed that 
dendritic cells treated by adiponectin had a lower production of IL-12p40, a 
chemoattractant for macrophages, and a declining expression of CD80, CD86 and 
histocompatibility complex class II (MHCII), all three proteins partake in T cell 
activation (Cooper & Khader, 2007; Tsang et al., 2011). These data indicate that immune 
response is partially mediated by adiponectin’s ability to alter dendritic cell functions. 
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Furthermore, adiponectin may exercise some control over Treg cell homeostasis, which 
was shown by the same group. During an experiment with co-cultures of T cells and 
adiponectin-treated dendritic cells, a reduction was noted in T cells proliferation and IL-2 
production, along with an increase in CD4+CD25+Foxp3+ Treg cells (Tsang et al., 2011).  
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CONCLUSION 
 
 
 In the past two decades the scientific community has grown extensively, 
discovering numerous factors and elucidating a myriad of pathophysiological processes. 
Hence the terms immunometabolism and metainflammation have been coined, but they 
are deceptively neat, serving as only shorthand terms ascribed to a wide array of cellular 
processes. While there are many unresolved questions connecting DIO to inflammation, 
immunity and ultimately infections and diseases, the basic road map has been outlined. 
Diet induced obesity leads to chronic low-grade inflammation, which in turn impairs 
body’s defenses, rendering the immune system incapable of differentiating between 
exogenous and endogenous threats, leaving the host exposed. As the immune system’s 
capabilities decline infections have an easier time penetrating the body and causing harm. 
The obese organism becomes its own poisonous pill. Instead of providing nourishment to 
the body, food, exerting hormonal control, activates inflammatory cascades, and initiates 
a positive feedback loop which negatively affects the body and future health (Weisberg et 
al., 2003; Curat et al., 2004; Lilja et al., 2012).  
 Today the scientific community is facing more questions than answers, but within 
these mysteries future opportunities to treat and prevent obesity-associated morbidities 
are apparent. The progress will not be quick and will inevitably consume vast sums of 
money, as well as time and effort by physicians, scientists, politicians and ordinary 
people, who ultimately bear the burden of disease diagnoses and treatment. 
  
63 
 
BIBLIOGRAPHY 
 
 
Abdullahi, M., Annibale, B., Capoccia, D., Tari, R., Lahner, E., Osborn, J., … Severi, C. 
(2008). The eradication of Helicobacter pylori is affected by body mass index 
(BMI). Obesity Surgery, 18(11), 1450–1454. doi:10.1007/s11695-008-9477-z 
Adam, R., McMaster, P., O’Grady, J. G., Castaing, D., Klempnauer, J. L., Jamieson, N., 
… Gonzalez, E. M. (2003). Evolution of liver transplantation in Europe: Report of 
the European Liver Transplant Registry. Liver Transplantation, 9(12), 1231–
1243. doi:10.1016/j.lts.2003.09.018 
Adkins, Y., & Kelley, D. S. (2010). Mechanisms underlying the cardioprotective effects 
of omega-3 polyunsaturated fatty acids. The Journal of Nutritional Biochemistry, 
21(9), 781–792. doi:10.1016/j.jnutbio.2009.12.004 
Aiello, L. C., & Wheeler, P. (1995). The Expensive-Tissue Hypothesis: The Brain and 
the Digestive System in Human and Primate Evolution. Current Anthropology, 
36(2), 199–221. doi:10.2307/2744104 
Al Massadi, O., Tschöp, M. H., & Tong, J. (2011). Ghrelin acylation and metabolic 
control. Peptides, 32(11), 2301–2308. doi:10.1016/j.peptides.2011.08.020 
Al-Sufyani, A. A., & Mahassni, S. H. (2011). Obesity and immune cells in Saudi 
females. Innate Immunity, 17(5), 439–450. doi:10.1177/1753425910372536 
Ali, Z., & Ulrik, C. S. (n.d.). Obesity and asthma: A coincidence or a causal relationship? 
A systematic review. Respiratory Medicine. doi:10.1016/j.rmed.2013.03.019 
Álvarez-Guardia, D., Palomer, X., Coll, T., Serrano, L., Rodríguez-Calvo, R., Davidson, 
M. M., … Vázquez-Carrera, M. (2011). PPARβ/δ activation blocks lipid-induced 
64 
 
inflammatory pathways in mouse heart and human cardiac cells. Biochimica et 
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1811(2), 59–67. 
doi:10.1016/j.bbalip.2010.11.002 
Andersen, D. K. (2013). Diabetes and cancer: placing the association in perspective. 
Current Opinion in Endocrinology, Diabetes, and Obesity, 20(2), 81–86. 
doi:10.1097/MED.0b013e32835eddd3 
Anfossi, G., Russo, I., & Trovati, M. (2009). Platelet dysfunction in central obesity. 
Nutrition, Metabolism and Cardiovascular Diseases, 19(6), 440–449. 
doi:10.1016/j.numecd.2009.01.006 
Armstrong, M. J., Houlihan, D. D., Bentham, L., Shaw, J. C., Cramb, R., Olliff, S., … 
Newsome, P. N. (2012). Presence and severity of non-alcoholic fatty liver disease 
in a large prospective primary care cohort. Journal of Hepatology, 56(1), 234–
240. doi:10.1016/j.jhep.2011.03.020 
Arner, E., Westermark, P. O., Spalding, K. L., Britton, T., Rydén, M., Frisén, J., … 
Arner, P. (2010). Adipocyte Turnover: Relevance to Human Adipose Tissue 
Morphology. Diabetes, 59(1), 105–109. doi:10.2337/db09-0942 
Arner, P., Andersson, D. P., Thörne, A., Wirén, M., Hoffstedt, J., Näslund, E., … Rydén, 
M. (2013). Variations in the Size of the Major Omentum Are Primarily 
Determined by Fat Cell Number. The Journal of Clinical Endocrinology & 
Metabolism, 98(5), E897–E901. doi:10.1210/jc.2012-4106 
Arnold, L., Henry, A., Poron, F., Baba-Amer, Y., van Rooijen, N., Plonquet, A., … 
Chazaud, B. (2007). Inflammatory monocytes recruited after skeletal muscle 
65 
 
injury switch into antiinflammatory macrophages to support myogenesis. Journal 
of Experimental Medicine, 204(5), 1057–1069. doi:10.1084/jem.20070075 
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., … Geissmann, 
F. (2007). Monitoring of Blood Vessels and Tissues by a Population of 
Monocytes with Patrolling Behavior. Science, 317(5838), 666–670. 
doi:10.1126/science.1142883 
Barrette, P.-O., & Schwertani, A. G. (2012). A closer look at the role of urotensin II in 
the metabolic syndrome. Frontiers in Neuroendocrine Science, 3, 165. 
doi:10.3389/fendo.2012.00165 
Baumgartl, J., Baudler, S., Scherner, M., Babaev, V., Makowski, L., Suttles, J., … 
Brüning, J. C. (2006). Myeloid lineage cell-restricted insulin resistance protects 
apolipoproteinE-deficient mice against atherosclerosis. Cell Metabolism, 3(4), 
247–256. doi:10.1016/j.cmet.2006.02.010 
Bentham Science Publisher, B. S. P. (2006). Metabolic Obesity: The Paradox Between 
Visceral and Subcutaneous Fat. Current Diabetes Reviews, 2(4), 367–373. 
doi:10.2174/1573399810602040367 
Berzigotti, A., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Morillas, R., 
… Group,  the P. H. C. (2011). Obesity is an independent risk factor for clinical 
decompensation in patients with cirrhosis. Hepatology, 54(2), 555–561. 
doi:10.1002/hep.24418 
Bhatia, V. K., Yun, S., Leung, V., Grimsditch, D. C., Benson, G. M., Botto, M. B., … 
Haskard, D. O. (2007). Complement C1q Reduces Early Atherosclerosis in Low-
66 
 
Density Lipoprotein Receptor-Deficient Mice. The American Journal of 
Pathology, 170(1), 416–426. doi:10.2353/ajpath.2007.060406 
Blüher, M. (2009). Adipose Tissue Dysfunction in Obesity. Experimental and Clinical 
Endocrinology &amp; Diabetes, 117(06), 241–250. doi:10.1055/s-0029-1192044 
Bracci, P. M. (2012). Obesity and pancreatic cancer: Overview of epidemiologic 
evidence and biologic mechanisms. Molecular Carcinogenesis, 51(1), 53–63. 
doi:10.1002/mc.20778 
Brahimi-Horn, M. C., & Pouysségur, J. (2007). Oxygen, a source of life and stress. FEBS 
Letters, 581(19), 3582–3591. doi:10.1016/j.febslet.2007.06.018 
Brasaemle, D. L., & Wolins, N. E. (2011). Packaging of Fat: An Evolving Model of 
Lipid Droplet Assembly and Expansion. Journal of Biological Chemistry, 287(4), 
2273–2279. doi:10.1074/jbc.R111.309088 
Brinkley, T. E., Kume, N., Mitsuoka, H., Phares, D. A., & Hagberg, J. M. (2008). 
Elevated Soluble Lectin-like Oxidized LDL Receptor-1 (sLOX-1) Levels in 
Obese Postmenopausal Women. Obesity, 16(6), 1454–1456. 
doi:10.1038/oby.2008.213 
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., … Burcelin, R. 
(2007). Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. 
Diabetes, 56(7), 1761–1772. doi:10.2337/db06-1491 
Cao, H. (2014). Adipocytokines in obesity and metabolic disease. Journal of 
Endocrinology, 220(2), T47–T59. doi:10.1530/JOE-13-0339 
67 
 
Carbone, F., La Rocca, C., & Matarese, G. (2012). Immunological functions of leptin and 
adiponectin. Biochimie, 94(10), 2082–2088. doi:10.1016/j.biochi.2012.05.018 
Cava, A. L., & Matarese, G. (2004). The weight of leptin in immunity. Nature Reviews 
Immunology, 4(5), 371–379. doi:10.1038/nri1350 
Cawthorn, W. P., & Sethi, J. K. (2008). TNF-α and adipocyte biology. FEBS Letters, 
582(1), 117–131. doi:10.1016/j.febslet.2007.11.051 
Cazzola, M., Calzetta, L., Lauro, D., Bettoncelli, G., Cricelli, C., Di Daniele, N., & 
Rogliani, P. (2013). Asthma and COPD in an Italian adult population: role of BMI 
considering the smoking habit. Respiratory Medicine, 107(9), 1417–1422. 
doi:10.1016/j.rmed.2013.04.021 
Cazzola, M., Calzetta, L., Lauro, D., Bettoncelli, G., Cricelli, C., Di Daniele, N., & 
Rogliani, P. (n.d.). 025 - 39 Asthma and COPD in an Italian adult population: 
Role of BMI considering the smoking habit. Respiratory Medicine. 
doi:10.1016/j.rmed.2013.04.021 
Ceddia, R. B., Somwar, R., Maida, A., Fang, X., Bikopoulos, G., & Sweeney, G. (2005). 
Globular adiponectin increases GLUT4 translocation and glucose uptake but 
reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia, 48(1), 132–
139. doi:10.1007/s00125-004-1609-y 
Cerqueira, R. M., Correia, M. R., Fernandes, C. D., Vilar, H., & Manso, M. C. (2013). 
Cumulative Helicobacter pylori eradication therapy in obese patients undergoing 
gastric bypass surgery. Obesity Surgery, 23(2), 145–149. doi:10.1007/s11695-
012-0747-4 
68 
 
Chae, J. S., Paik, J. K., Kang, R., Kim, M., Choi, Y., Lee, S.-H., & Lee, J. H. (2013). 
Mild weight loss reduces inflammatory cytokines, leukocyte count, and oxidative 
stress in overweight and moderately obese participants treated for 3 years with 
dietary modification. Nutrition Research, 33(3), 195–203. 
doi:10.1016/j.nutres.2013.01.005 
Chaldakov, G. N., Fiore, M., Tonchev, A. B., & Aloe, L. (2010). Neuroadipology: a 
novel component of neuroendocrinology. Cell Biology International, 34(10), 
1051–1053. doi:10.1042/CBI20100509 
Charrière, G., Cousin, B., Arnaud, E., André, M., Bacou, F., Pénicaud, L., & Casteilla, L. 
(2003). Preadipocyte Conversion to Macrophage EVIDENCE OF PLASTICITY. 
Journal of Biological Chemistry, 278(11), 9850–9855. 
doi:10.1074/jbc.M210811200 
Chen, C., Yang, H., Yang, W., Liu, C., Chen, P., You, S., … Chen, C. (2008). Metabolic 
Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C 
Infection: A Follow-up Study in Taiwan. Gastroenterology, 135(1), 111–121. 
doi:10.1053/j.gastro.2008.03.073 
Chua, S. C., Chung, W. K., Wu-Peng, X. S., Zhang, Y., Liu, S. M., Tartaglia, L., & 
Leibel, R. L. (1996). Phenotypes of mouse diabetes and rat fatty due to mutations 
in the OB (leptin) receptor. Science (New York, N.Y.), 271(5251), 994–996. 
Ciesla, D. J., Moore, E. E., Johnson, J. L., Burch, J. M., Cothren, C. C., & Sauaia, A. 
(2006). Obesity Increases Risk of Organ Failure after Severe Trauma. Journal of 
69 
 
the American College of Surgeons, 203(4), 539–545. 
doi:10.1016/j.jamcollsurg.2006.06.029 
Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., … Obin, M. S. 
(2005). Adipocyte death defines macrophage localization and function in adipose 
tissue of obese mice and humans. Journal of Lipid Research, 46(11), 2347–2355. 
doi:10.1194/jlr.M500294-JLR200 
Cooper, A. M., & Khader, S. A. (2007). IL-12p40: an inherently agonistic cytokine. 
Trends in Immunology, 28(1), 33–38. doi:10.1016/j.it.2006.11.002 
Cousin, B., Munoz, O., Andre, M., Fontanilles, A. M., Dani, C., Cousin, J. L., … 
Énicaud, L. P. (1999). A role for preadipocytes as macrophage-like cells. The 
FASEB Journal, 13(2), 305–312. 
Curat, C. A., Miranville, A., Sengenès, C., Diehl, M., Tonus, C., Busse, R., & 
Bouloumié, A. (2004). From Blood Monocytes to Adipose Tissue-Resident 
Macrophages Induction of Diapedesis by Human Mature Adipocytes. Diabetes, 
53(5), 1285–1292. doi:10.2337/diabetes.53.5.1285 
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011). The Inflammasome NLRs in Immunity, 
Inflammation, and Associated Diseases. Annual Review of Immunology, 29(1), 
707–735. doi:10.1146/annurev-immunol-031210-101405 
Davis, J. E., Braucher, D. R., Walker-Daniels, J., & Spurlock, M. E. (2011). Absence of 
Tlr2 protects against high-fat diet-induced inflammation and results in greater 
insulin-stimulated glucose transport in cultured adipocytes. The Journal of 
Nutritional Biochemistry, 22(2), 136–141. doi:10.1016/j.jnutbio.2009.12.008 
70 
 
Davis, J. E., Gabler, N. K., Walker-Daniels, J., & Spurlock, M. E. (2008). Tlr-4 
Deficiency Selectively Protects Against Obesity Induced by Diets High in 
Saturated Fat. Obesity, 16(6), 1248–1255. doi:10.1038/oby.2008.210 
Davis, J., Gabler, N., Walker-Daniels, J., & Spurlock, M. (2009). The c-Jun N-Terminal 
Kinase Mediates the Induction of Oxidative Stress and Insulin Resistance by 
Palmitate and Toll-like Receptor 2 and 4 Ligands in 3T3-L1 Adipocytes. 
Hormone and Metabolic Research, 41(07), 523–530. doi:10.1055/s-0029-
1202852 
Dawood, F. S., Iuliano, A. D., Reed, C., Meltzer, M. I., Shay, D. K., Cheng, P.-Y., … 
Widdowson, M.-A. (2012). Estimated global mortality associated with the first 12 
months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. 
The Lancet Infectious Diseases, 12(9), 687–695. doi:10.1016/S1473-
3099(12)70121-4 
De Rosa, V., Procaccini, C., Calì, G., Pirozzi, G., Fontana, S., Zappacosta, S., … 
Matarese, G. (2007). A Key Role of Leptin in the Control of Regulatory T Cell 
Proliferation. Immunity, 26(2), 241–255. doi:10.1016/j.immuni.2007.01.011 
DeFronzo, R. A. (2010). Insulin resistance, lipotoxicity, type 2 diabetes and 
atherosclerosis: the missing links. The Claude Bernard Lecture 2009. 
Diabetologia, 53(7), 1270–1287. doi:10.1007/s00125-010-1684-1 
Dixit, V. D. (2008). Adipose-immune interactions during obesity and caloric restriction: 
reciprocal mechanisms regulating immunity and health span. Journal of 
Leukocyte Biology, 84(4), 882–892. doi:10.1189/jlb.0108028 
71 
 
Drolet, R., Richard, C., Sniderman, A. D., Mailloux, J., Fortier, M., Huot, C., … 
Tchernof, A. (2007). Hypertrophy and hyperplasia of abdominal adipose tissues 
in women. International Journal of Obesity, 32(2), 283–291. 
doi:10.1038/sj.ijo.0803708 
Ehses, J. A., Meier, D. T., Wueest, S., Rytka, J., Boller, S., Wielinga, P. Y., … Donath, 
M. Y. (2010). Toll-like receptor 2-deficient mice are protected from insulin 
resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia, 
53(8), 1795–1806. doi:10.1007/s00125-010-1747-3 
Elgazar-Carmon, V., Rudich, A., Hadad, N., & Levy, R. (2008). Neutrophils transiently 
infiltrate intra-abdominal fat early in the course of high-fat feeding. Journal of 
Lipid Research, 49(9), 1894–1903. doi:10.1194/jlr.M800132-JLR200 
El-Gilany, A.-H., & Hammad, S. (2010). Body mass index and obstetric outcomes in 
pregnant in Saudi Arabia: a prospective cohort study. Annals of Saudi Medicine, 
0(0), 0. doi:10.4103/0256-4947.67075 
Erbay, E., Babaev, V. R., Mayers, J. R., Makowski, L., Charles, K. N., Snitow, M. E., … 
Hotamisligil, G. S. (2009). Reducing endoplasmic reticulum stress through a 
macrophage lipid chaperone alleviates atherosclerosis. Nature Medicine, 15(12), 
1383–1391. doi:10.1038/nm.2067 
Erren, T. ., & Erren, M. (2004). Can fat explain the human brain’s big bang evolution?—
Horrobin’s leads for comparative and functional genomics. Prostaglandins, 
Leukotrienes and Essential Fatty Acids, 70(4), 345–347. 
doi:10.1016/j.plefa.2003.12.008 
72 
 
Estadella, D., bora, da Penha Oller do Nascimento, C. M., Oyama, L. M., Ribeiro, E. B., 
D&#xe2, … de Piano, A. (2013). Lipotoxicity: Effects of Dietary Saturated and 
Transfatty Acids. Mediators of Inflammation, 2013. doi:10.1155/2013/137579 
European Liver Transplant Registry - ELTR. (n.d.). Retrieved July 24, 2014, from 
http://www.eltr.org/spip.php?article162 
Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004). PPARs and the complex journey to 
obesity. Nature Medicine, 10(4), 355–361. doi:10.1038/nm1025 
Everhart, J. E., Lok, A. S., Kim, H., Morgan, T. R., Lindsay, K. L., Chung, R. T., … 
Ghany, M. G. (2009). Weight-Related Effects on Disease Progression in the 
Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. 
Gastroenterology, 137(2), 549–557. doi:10.1053/j.gastro.2009.05.007 
Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., … 
O’Rahilly, S. (2002). Beneficial effects of leptin on obesity, T cell 
hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human 
congenital leptin deficiency. Journal of Clinical Investigation, 110(8), 1093–
1103. doi:10.1172/JCI15693 
Feng, D., Tang, Y., Kwon, H., Zong, H., Hawkins, M., Kitsis, R. N., & Pessin, J. E. 
(2011). High-Fat Diet–Induced Adipocyte Cell Death Occurs Through a 
Cyclophilin D Intrinsic Signaling Pathway Independent of Adipose Tissue 
Inflammation. Diabetes, 60(8), 2134–2143. doi:10.2337/db10-1411 
Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., … Mathis, D. 
(2009). Lean, but not obese, fat is enriched for a unique population of regulatory 
73 
 
T cells that affect metabolic parameters. Nature Medicine, 15(8), 930–939. 
doi:10.1038/nm.2002 
Fezeu, L., Julia, C., Henegar, A., Bitu, J., Hu, F. B., Grobbee, D. E., … Czernichow, S. 
(2011). Obesity is associated with higher risk of intensive care unit admission and 
death in influenza A (H1N1) patients: a systematic review and meta-analysis. 
Obesity Reviews, 12(8), 653–659. doi:10.1111/j.1467-789X.2011.00864.x 
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., … 
Ezzati, M. (12). National, regional, and global trends in body-mass index since 
1980: systematic analysis of health examination surveys and epidemiological 
studies with 960 country-years and 9·1 million participants. The Lancet, 
377(9765), 557–567. doi:10.1016/S0140-6736(10)62037-5 
Fleischmann, E., Kurz, A., Niedermayr, M., Schebesta, K., Kimberger, O., Sessler, D. I., 
… Prager, G. (2005). Tissue Oxygenation in Obese and Non-obese Patients 
During Laparoscopy. Obesity Surgery, 15(6), 813–819. 
doi:10.1381/0960892054222867 
Folkman, J., Hahnfeldt, P., & Hlatky, L. (2000). Cancer: looking outside the genome. 
Nature Reviews Molecular Cell Biology, 1(1), 76–79. doi:10.1038/35036100 
Frayn, K. (2002). Adipose tissue as a buffer for daily lipid flux. Diabetologia, 45(9), 
1201–1210. doi:10.1007/s00125-002-0873-y 
Friedman, J. M., & Halaas, J. L. (1998). Leptin and the regulation of body weight in 
mammals. Nature, 395(6704), 763–770. doi:10.1038/27376 
74 
 
Frisard, M. I., McMillan, R. P., Marchand, J., Wahlberg, K. A., Wu, Y., Voelker, K. A., 
… Hulver, M. W. (2010). Toll-like receptor 4 modulates skeletal muscle substrate 
metabolism. AJP: Endocrinology and Metabolism, 298(5), E988–E998. 
doi:10.1152/ajpendo.00307.2009 
Fryar, Cheryl D., Carroll, Margaret D., & Ogden, Cynthis L. (2012). Overweight, 
Obesity, and Extreme Obesity Among Adults: United States, Trends 1960-1962 
Through 2009-2010. Retrieved from 
http://www.cdc.gov.ezproxy.bu.edu/nchs/data/hestat/obesity_adult_09_10/obesity
_adult_09_10.htm 
Fujimoto, T., & Parton, R. G. (2011). Not Just Fat: The Structure and Function of the 
Lipid Droplet. Cold Spring Harbor Perspectives in Biology, 3(3), a004838–
a004838. doi:10.1101/cshperspect.a004838 
Fujisaka, S., Usui, I., Ikutani, M., Aminuddin, A., Takikawa, A., Tsuneyama, K., … 
Tobe, K. (2013). Adipose tissue hypoxia induces inflammatory M1 polarity of 
macrophages in an HIF-1α-dependent and HIF-1α-independent manner in obese 
mice. Diabetologia, 56(6), 1403–1412. doi:10.1007/s00125-013-2885-1 
Galgani, M., & Matarese, G. (2010). Editorial: Acute inflammation in obesity: IL-17A in 
the middle of the battle. Journal of Leukocyte Biology, 87(1), 17–18. 
doi:10.1189/jlb.0809530 
Galic, S., Oakhill, J. S., & Steinberg, G. R. (2010). Adipose tissue as an endocrine organ. 
Molecular and Cellular Endocrinology, 316(2), 129–139. 
doi:10.1016/j.mce.2009.08.018 
75 
 
Gani, O. A. B. S. M., & Sylte, I. (2008). Molecular recognition of Docosahexaenoic acid 
by peroxisome proliferator-activated receptors and retinoid-X receptor α. Journal 
of Molecular Graphics and Modelling, 27(2), 217–224. 
doi:10.1016/j.jmgm.2008.04.008 
Gastaldelli, A., & Basta, G. (2010). Ectopic fat and cardiovascular disease: What is the 
link? Nutrition, Metabolism and Cardiovascular Diseases, 20(7), 481–490. 
doi:10.1016/j.numecd.2010.05.005 
Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? 
Nature Reviews Cancer, 4(11), 891–899. doi:10.1038/nrc1478 
Geerlings, S. E., & Hoepelman, A. I. . (1999). Immune dysfunction in patients with 
diabetes mellitus (DM). FEMS Immunology & Medical Microbiology, 26(3-4), 
259–265. doi:10.1111/j.1574-695X.1999.tb01397.x 
Ghanim, H., Aljada, A., Hofmeyer, D., Syed, T., Mohanty, P., & Dandona, P. (2004). 
Circulating Mononuclear Cells in the Obese Are in a Proinflammatory State. 
Circulation, 110(12), 1564–1571. doi:10.1161/01.CIR.0000142055.53122.FA 
Gilmore, Thomas (n.d.) .Boston University Biology Department. “NF-kB Target Genes”.  
Retreived on 7/22/14 from http://www.bu.edu/nf-kb/gene-resources/target-genes/. 
(n.d.). Retrieved July 23, 2014, from http://www.bu.edu/nf-kb/gene-
resources/target-genes/ 
Giorgio, V., Prono, F., Graziano, F., & Nobili, V. (2013). Pediatric non alcoholic fatty 
liver disease: old and new concepts on development, progression, metabolic 
76 
 
insight and potential treatment targets. BMC Pediatrics, 13(1), 40. 
doi:10.1186/1471-2431-13-40 
Goossens, G. H., Bizzarri, A., Venteclef, N., Essers, Y., Cleutjens, J. P., Konings, E., … 
Blaak, E. E. (2011). Increased Adipose Tissue Oxygen Tension in Obese 
Compared With Lean Men Is Accompanied by Insulin Resistance, Impaired 
Adipose Tissue Capillarization, and Inflammation. Circulation, 124(1), 67–76. 
doi:10.1161/CIRCULATIONAHA.111.027813 
Gordon, S. (2007). The macrophage: Past, present and future. European Journal of 
Immunology, 37(S1), S9–S17. doi:10.1002/eji.200737638 
Gordy, C., Pua, H., Sempowski, G. D., & He, Y.-W. (2011). Regulation of steady-state 
neutrophil homeostasis by macrophages. Blood, 117(2), 618–629. 
doi:10.1182/blood-2010-01-265959 
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A., & Karin, M. (2013). Inflammation, 
Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis 
and Pancreatic Cancer. Gastroenterology, 144(6), 1199–1209.e4. 
doi:10.1053/j.gastro.2013.02.007 
Gupta, A. K., Johnson, W. D., Johannsen, D., & Ravussin, E. (2013). Cardiovascular risk 
escalation with caloric excess: a prospective demonstration of the mechanics in 
healthy adults. Cardiovascular Diabetology, 12(1), 23. doi:10.1186/1475-2840-
12-23 
Gustafson, B., Gogg, S., Hedjazifar, S., Jenndahl, L., Hammarstedt, A., & Smith, U. 
(2009). Inflammation and impaired adipogenesis in hypertrophic obesity in man. 
77 
 
American Journal of Physiology - Endocrinology and Metabolism, 297(5), E999–
E1003. doi:10.1152/ajpendo.00377.2009 
Gustafson, B., Hammarstedt, A., Hedjazifar, S., & Smith, U. (2013). Restricted 
Adipogenesis in Hypertrophic Obesity The Role of WISP2, WNT, and BMP4. 
Diabetes, 62(9), 2997–3004. doi:10.2337/db13-0473 
Halberg, N., Wernstedt-Asterholm, I., & Scherer, P. E. (2008). The adipocyte as an 
endocrine cell. Endocrinology and Metabolism Clinics of North America, 37(3), 
753–768, x–xi. doi:10.1016/j.ecl.2008.07.002 
Haneklaus, M., O’Neill, L. A., & Coll, R. C. (2013). Modulatory mechanisms controlling 
the NLRP3 inflammasome in inflammation: recent developments. Current 
Opinion in Immunology, 25(1), 40–45. doi:10.1016/j.coi.2012.12.004 
Harwood Jr., H. J. (2012). The adipocyte as an endocrine organ in the regulation of 
metabolic homeostasis. Neuropharmacology, 63(1), 57–75. 
doi:10.1016/j.neuropharm.2011.12.010 
Hausman, G. J., Poulos, S. P., Richardson, R. L., Barb, C. R., Andacht, T., Kirk, H. C., & 
Mynatt, R. L. (2006). Secreted proteins and genes in fetal and neonatal pig 
adipose tissue and stromal-vascular cells. Journal of Animal Science, 84(7), 
1666–1681. doi:10.2527/jas.2005-539 
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., 
… Golenbock, D. T. (2013). NLRP3 is activated in Alzheimer/’s disease and 
contributes to pathology in APP/PS1 mice. Nature, 493(7434), 674–678. 
doi:10.1038/nature11729 
78 
 
Himes, R. W., & Smith, C. W. (2010). Tlr2 is critical for diet-induced metabolic 
syndrome in a murine model. The FASEB Journal, 24(3), 731–739. 
doi:10.1096/fj.09-141929 
Hirai, S., Takahashi, N., Goto, T., Lin, S., Uemura, T., Yu, R., & Kawada, T. (2010). 
Functional Food Targeting the Regulation of Obesity-Induced Inflammatory 
Responses and Pathologies. Mediators of Inflammation, 2010, 1–8. 
doi:10.1155/2010/367838 
Holland, W. L., Bikman, B. T., Wang, L.-P., Yuguang, G., Sargent, K. M., Bulchand, S., 
… Summers, S. A. (2011). Lipid-induced insulin resistance mediated by the 
proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide 
biosynthesis in mice. Journal of Clinical Investigation, 121(5), 1858–1870. 
doi:10.1172/JCI43378 
Hong, C., Walczak, R., Dhamko, H., Bradley, M. N., Marathe, C., Boyadjian, R., … 
Tontonoz, P. (2011). Constitutive activation of LXR in macrophages regulates 
metabolic and inflammatory gene expression: identification of ARL7 as a direct 
target. Journal of Lipid Research, 52(3), 531–539. doi:10.1194/jlr.M010686 
Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., … 
Shimomura, I. (2007). Adipose Tissue Hypoxia in Obesity and Its Impact on 
Adipocytokine Dysregulation. Diabetes, 56(4), 901–911. doi:10.2337/db06-0911 
Inoue, K., Arai, Y., Kurihara, H., Kita, T., & Sawamura, T. (2005). Overexpression of 
Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Induces 
79 
 
Intramyocardial Vasculopathy in Apolipoprotein E–Null Mice. Circulation 
Research, 97(2), 176–184. doi:10.1161/01.RES.0000174286.73200.d4 
Ioannou, G. N., Weiss, N. S., Boyko, E. J., Kowdley, K. V., Kahn, S. E., Carithers Jr, R. 
L., … Dominitz, J. A. (2005). Is central obesity associated with cirrhosis-related 
death or hospitalization? A population-based, cohort study. Clinical 
Gastroenterology and Hepatology, 3(1), 67–74. doi:10.1016/S1542-
3565(04)00442-2 
Jämsen, E., Nevalainen, P., Eskelinen, A., Huotari, K., Kalliovalkama, J., & Moilanen, T. 
(2012). Obesity, diabetes, and preoperative hyperglycemia as predictors of 
periprosthetic joint infection: a single-center analysis of 7181 primary hip and 
knee replacements for osteoarthritis. The Journal of Bone and Joint Surgery. 
American Volume, 94(14), e101. doi:10.2106/JBJS.J.01935 
Jernås, M., Palming, J., Sjöholm, K., Jennische, E., Svensson, P.-A., Gabrielsson, B. G., 
… Lönn, M. (2006). Separation of human adipocytes by size: hypertrophic fat 
cells display distinct gene expression. The FASEB Journal, 20(9), 1540–1542. 
doi:10.1096/fj.05-5678fje 
Jo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A. E., … Periwal, V. (2009). 
Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLoS 
Computational Biology, 5(3), e1000324. doi:10.1371/journal.pcbi.1000324 
Jo, J., Shreif, Z., & Periwal, V. (2012). Quantitative dynamics of adipose cells. 
Adipocyte, 1(2), 80–88. doi:10.4161/adip.19705 
80 
 
Johnson, A. R., Justin Milner, J., & Makowski, L. (2012). The inflammation highway: 
metabolism accelerates inflammatory traffic in obesity. Immunological Reviews, 
249(1), 218–238. doi:10.1111/j.1600-065X.2012.01151.x 
Johnson, P. R., & Hirsch, J. (1972). Cellularity of adipose depots in six strains of 
genetically obese mice. Journal of Lipid Research, 13(1), 2–11. 
Kabon, B., Nagele, A., Reddy, D., Eagon, C., Fleshman, J. W., Sessler, D. I., & Kurz, A. 
(2004). Obesity Decreases Perioperative Tissue Oxygenation. Anesthesiology, 
100(2), 274. 
Kamali, K., Abbasi, M. A., Behzadi, A. H., Mortazavi, A., & Bastani, B. (2010). 
Incidence and Risk Factors of Transplant Renal Artery Stenosis in Living 
Unrelated Donor Renal Transplantation. Journal of Renal Care, 36(3), 149–152. 
doi:10.1111/j.1755-6686.2010.00188.x 
KANNEL, W. B., BRAND, N., SKINNER, J., DAWBER, T. R., & MCNAMARA, P. 
M. (1967). The Relation of Adiposity to Blood Pressure and Development of 
HypertensionThe Framingham Study. Annals of Internal Medicine, 67(1), 48–59. 
doi:10.7326/0003-4819-67-1-48 
Karpe, F., Fielding, B. A., Ilic, V., Macdonald, I. A., Summers, L. K. M., & Frayn, K. N. 
(2002). Impaired Postprandial Adipose Tissue Blood Flow Response Is Related to 
Aspects of Insulin Sensitivity. Diabetes, 51(8), 2467–2473. 
doi:10.2337/diabetes.51.8.2467 
Kelly, K. J., Wu, P., Patterson, C. E., Temm, C., & Dominguez, J. H. (2008). LOX-1 and 
inflammation: a new mechanism for renal injury in obesity and diabetes. 
81 
 
American Journal of Physiology - Renal Physiology, 294(5), F1136–F1145. 
doi:10.1152/ajprenal.00396.2007 
Kennedy, G. C. (1953). The role of depot fat in the hypothalamic control of food intake 
in the rat. Proceedings of the Royal Society of London. Series B, Containing 
Papers of a Biological Character. Royal Society (Great Britain), 140(901), 578–
596. 
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, 
H., … Sabatini, D. M. (2002). mTOR Interacts with Raptor to Form a Nutrient-
Sensitive Complex that Signals to the Cell Growth Machinery. Cell, 110(2), 163–
175. doi:10.1016/S0092-8674(02)00808-5 
Kim, E.-J., Jin, B.-H., & Bae, K.-H. (2011). Periodontitis and Obesity: A Study of the 
Fourth Korean National Health and Nutrition Examination Survey. Journal of 
Periodontology, 82(4), 533–542. doi:10.1902/jop.2010.100274 
Kim, H. Y., Lee, H. J., Chang, Y.-J., Pichavant, M., Shore, S. A., Fitzgerald, K. A., … 
Umetsu, D. T. (2014). Interleukin-17-producing innate lymphoid cells and the 
NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. 
Nature Medicine, 20(1), 54–61. doi:10.1038/nm.3423 
Kim, J. A., & Park, H. S. (2008). White blood cell count and abdominal fat distribution in 
female obese adolescents. Metabolism, 57(10), 1375–1379. 
doi:10.1016/j.metabol.2008.05.005 
Kim, K. H., Song, M. J., Chung, J., Park, H., & Kim, J. B. (2005). Hypoxia inhibits 
adipocyte differentiation in a HDAC-independent manner. Biochemical and 
82 
 
Biophysical Research Communications, 333(4), 1178–1184. 
doi:10.1016/j.bbrc.2005.06.023 
Kim, M.-S., Pak, Y. K., Jang, P.-G., Namkoong, C., Choi, Y.-S., Won, J.-C., … Lee, K.-
U. (2006). Role of hypothalamic Foxo1 in the regulation of food intake and 
energy homeostasis. Nature Neuroscience, 9(7), 901–906. doi:10.1038/nn1731 
Kolls, J. K., & Lindén, A. (2004). Interleukin-17 Family Members and Inflammation. 
Immunity, 21(4), 467–476. doi:10.1016/j.immuni.2004.08.018 
Kosteli, A., Sugaru, E., Haemmerle, G., Martin, J. F., Lei, J., Zechner, R., & Ferrante, A. 
W. (2010). Weight loss and lipolysis promote a dynamic immune response in 
murine adipose tissue. Journal of Clinical Investigation, 120(10), 3466–3479. 
doi:10.1172/JCI42845 
Kromhout, D., Yasuda, S., Geleijnse, J. M., & Shimokawa, H. (2011). Fish oil and 
omega-3 fatty acids in cardiovascular disease: do they really work? European 
Heart Journal, 33(4), 436–443. doi:10.1093/eurheartj/ehr362 
Kuk, J. L., & Ardern, C. I. (2009). Are Metabolically Normal but Obese Individuals at 
Lower Risk for All-Cause Mortality? Diabetes Care, 32(12), 2297–2299. 
doi:10.2337/dc09-0574 
Kumar, H., Kawai, T., & Akira, S. (2011). Pathogen Recognition by the Innate Immune 
System. International Reviews of Immunology, 30(1), 16–34. 
doi:10.3109/08830185.2010.529976 
83 
 
Kuo, J. H., Wong, M. S., Perez, R. V., Li, C.-S., Lin, T.-C., & Troppmann, C. (2012). 
Renal Transplant Wound Complications in the Modern Era of Obesity. Journal of 
Surgical Research, 173(2), 216–223. doi:10.1016/j.jss.2011.05.030 
Kusminski, C. M., & Scherer, P. E. (2009). The Road From Discovery to Clinic: 
Adiponectin as a Biomarker of Metabolic Status. Clinical Pharmacology & 
Therapeutics, 86(6), 592–595. doi:10.1038/clpt.2009.155 
Kusminski, C. M., Shetty, S., Orci, L., Unger, R. H., & Scherer, P. E. (2009). Diabetes 
and apoptosis: lipotoxicity. Apoptosis, 14(12), 1484–1495. doi:10.1007/s10495-
009-0352-8 
Kusunoki, T., Morimoto, T., Nishikomori, R., Heike, T., Ito, M., Hosoi, S., & Nakahata, 
T. (2008). Obesity and the prevalence of allergic diseases in schoolchildren. 
Pediatric Allergy and Immunology, 19(6), 527–534. doi:10.1111/j.1399-
3038.2007.00686.x 
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd-Jones, D., & 
Sowers, J. (2013). Obesity-Related Hypertension: Pathogenesis, Cardiovascular 
Risk, and Treatment. The Journal of Clinical Hypertension, 15(1), 14–33. 
doi:10.1111/jch.12049 
Lee, I.-C., Huang, Y.-H., Chan, C.-C., Huo, T.-I., Chu, C.-J., Lai, C.-R., … Lee, S.-D. 
(2011). Impact of body mass index and viral load on liver histology in hepatitis B 
e antigen-negative chronic hepatitis B. Clinical Nutrition, 30(5), 647–652. 
doi:10.1016/j.clnu.2011.05.001 
84 
 
Lee, J. Y., Zhao, L., Youn, H. S., Weatherill, A. R., Tapping, R., Feng, L., … Hwang, D. 
H. (2004). Saturated Fatty Acid Activates but Polyunsaturated Fatty Acid Inhibits 
Toll-like Receptor 2 Dimerized with Toll-like Receptor 6 or 1. Journal of 
Biological Chemistry, 279(17), 16971–16979. doi:10.1074/jbc.M312990200 
Lehr, S., Hartwig, S., Lamers, D., Famulla, S., Müller, S., Hanisch, F.-G., … Eckel, J. 
(2012). Identification and Validation of Novel Adipokines Released from Primary 
Human Adipocytes. Molecular & Cellular Proteomics, 11(1), M111.010504. 
doi:10.1074/mcp.M111.010504 
Li, D., & Mehta, J. L. (2000). Antisense to LOX-1 Inhibits Oxidized LDL–Mediated 
Upregulation of Monocyte Chemoattractant Protein-1 and Monocyte Adhesion to 
Human Coronary Artery Endothelial Cells. Circulation, 101(25), 2889–2895. 
doi:10.1161/01.CIR.101.25.2889 
Li, P., Lu, M., Nguyen, M. T. A., Bae, E. J., Chapman, J., Feng, D., … Olefsky, J. M. 
(2010). Functional Heterogeneity of CD11c-positive Adipose Tissue 
Macrophages in Diet-induced Obese Mice. Journal of Biological Chemistry, 
285(20), 15333–15345. doi:10.1074/jbc.M110.100263 
Lilja, H. E., Morrison, W. A., Han, X.-L., Palmer, J., Taylor, C., Tee, R., … Abberton, K. 
M. (2012). An Adipoinductive Role of Inflammation in Adipose Tissue 
Engineering: Key Factors in the Early Development of Engineered Soft Tissues. 
Stem Cells and Development, 22(10), 1602–1613. doi:10.1089/scd.2012.0451 
Lin, Q., Lee, Y.-J., & Yun, Z. (2006). Differentiation Arrest by Hypoxia. Journal of 
Biological Chemistry, 281(41), 30678–30683. doi:10.1074/jbc.C600120200 
85 
 
Liu, B., Balkwill, A., Reeves, G., Beral, V., & on behalf of the Million Women Study 
Collaborators. (2010). Body mass index and risk of liver cirrhosis in middle aged 
UK women: prospective study. BMJ, 340(mar11 1), c912–c912. 
doi:10.1136/bmj.c912 
Liu, B. C., McIntyre, P., Kaldor, J. M., Quinn, H. E., Ridda, I., & Banks, E. (2012). 
Pertussis in Older Adults: Prospective Study of Risk Factors and Morbidity. 
Clinical Infectious Diseases, 55(11), 1450–1456. doi:10.1093/cid/cis627 
Liu, J., Divoux, A., Sun, J., Zhang, J., Clément, K., Glickman, J. N., … Shi, G.-P. (2009). 
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-
induced obesity and diabetes in mice. Nature Medicine, 15(8), 940–945. 
doi:10.1038/nm.1994 
Liu, P.-C., Kieckhefer, G. M., & Gau, B.-S. (2013). A systematic review of the 
association between obesity and asthma in children. Journal of Advanced 
Nursing, 69(7), 1446–1465. doi:10.1111/jan.12129 
Lloyd-Jones, D., Adams, R., Carnethon, M., Simone, G. D., Ferguson, T. B., Flegal, K., 
… Hong, Y. (2009). Heart Disease and Stroke Statistics—2009 Update A Report 
From the American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation, 119(3), e21–e181. 
doi:10.1161/CIRCULATIONAHA.108.191261 
Lönn, M., Mehlig, K., Bengtsson, C., & Lissner, L. (2010). Adipocyte size predicts 
incidence of type 2 diabetes in women. The FASEB Journal, 24(1), 326–331. 
doi:10.1096/fj.09-133058 
86 
 
Lord, G. M., Matarese, G., Howard, J. K., Baker, R. J., Bloom, S. R., & Lechler, R. I. 
(1998). Leptin modulates the T-cell immune response and reverses starvation-
induced immunosuppression. Nature, 394(6696), 897–901. doi:10.1038/29795 
Louie JK, A. M. (2009). Factors associated with death or hospitalization due to pandemic 
2009 influenza a(h1n1) infection in california. JAMA, 302(17), 1896–1902. 
doi:10.1001/jama.2009.1583 
Lukens, J. R., Dixit, V. D., & Kanneganti, T.-D. (2011). Inflammasome Activation in 
Obesity-related Inflammatory Diseases and Autoimmunity. Discovery Medicine, 
12(62), 65–74. 
Lumeng, C. N. (2013). Innate immune activation in obesity. Molecular Aspects of 
Medicine, 34(1), 12–29. doi:10.1016/j.mam.2012.10.002 
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007). Obesity induces a phenotypic 
switch in adipose tissue macrophage polarization. Journal of Clinical 
Investigation, 117(1), 175–184. doi:10.1172/JCI29881 
Lumeng, C. N., DelProposto, J. B., Westcott, D. J., & Saltiel, A. R. (2008). Phenotypic 
Switching of Adipose Tissue Macrophages With Obesity Is Generated by 
Spatiotemporal Differences in Macrophage Subtypes. Diabetes, 57(12), 3239–
3246. doi:10.2337/db08-0872 
Lumeng, C. N., DeYoung, S. M., Bodzin, J. L., & Saltiel, A. R. (2007). Increased 
Inflammatory Properties of Adipose Tissue Macrophages Recruited During Diet-
Induced Obesity. Diabetes, 56(1), 16–23. doi:10.2337/db06-1076 
87 
 
Lumeng, C. N., Maillard, I., & Saltiel, A. R. (2009). T-ing up inflammation in fat. Nature 
Medicine, 15(8), 846–847. doi:10.1038/nm0809-846 
Lynch, L., O’Shea, D., Winter, D. C., Geoghegan, J., Doherty, D. G., & O’Farrelly, C. 
(2009). Invariant NKT cells and CD1d+ cells amass in human omentum and are 
depleted in patients with cancer and obesity. European Journal of Immunology, 
39(7), 1893–1901. doi:10.1002/eji.200939349 
Ma, X., Lim, U., Park, Y., Mayne, S. T., Wang, R., Hartge, P., … Schatzkin, A. (2009). 
Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US 
Cohort. American Journal of Epidemiology, 169(12), 1492–1499. 
doi:10.1093/aje/kwp074 
MacLaren, R., Cui, W., & Cianflone, K. (2008). Adipokines and the Immune System: An 
Adipocentric View. In J. D. Lambris (Ed.), Current Topics in Complement II (pp. 
1–21). Springer US. Retrieved from 
http://link.springer.com.ezproxy.bu.edu/chapter/10.1007/978-0-387-78952-1_1 
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., … 
Matsuzawa, Y. (2002). Diet-induced insulin resistance in mice lacking 
adiponectin/ACRP30. Nature Medicine, 8(7), 731–737. doi:10.1038/nm724 
Majka, S. M., Barak, Y., & Klemm, D. J. (2011). Concise Review: Adipocyte Origins: 
Weighing the Possibilities. STEM CELLS, 29(7), 1034–1040. 
doi:10.1002/stem.653 
Mamane, Y., Chung Chan, C., Lavallee, G., Morin, N., Xu, L.-J., Huang, J., … Mancini, 
J. A. (2009). The C3a Anaphylatoxin Receptor Is a Key Mediator of Insulin 
88 
 
Resistance and Functions by Modulating Adipose Tissue Macrophage Infiltration 
and Activation. Diabetes, 58(9), 2006–2017. doi:10.2337/db09-0323 
Manco, M., Putignani, L., & Bottazzo, G. F. (2010). Gut microbiota, lipopolysaccharides, 
and innate immunity in the pathogenesis of obesity and cardiovascular risk. 
Endocrine Reviews, 31(6), 817–844. doi:10.1210/er.2009-0030 
Mancuso, P. (2013). Obesity and respiratory infections: does excess adiposity weigh 
down host defense? Pulmonary Pharmacology & Therapeutics, 26(4), 412–419. 
doi:10.1016/j.pupt.2012.04.006 
Mancuso, P., Canetti, C., Gottschalk, A., Tithof, P. K., & Peters-Golden, M. (2004). 
Leptin augments alveolar macrophage leukotriene synthesis by increasing 
phospholipase activity and enhancing group IVC iPLA2 (cPLA2γ) protein 
expression. American Journal of Physiology - Lung Cellular and Molecular 
Physiology, 287(3), L497–L502. doi:10.1152/ajplung.00010.2004 
Mantell, B. S., Stefanovic-Racic, M., Yang, X., Dedousis, N., Sipula, I. J., & O’Doherty, 
R. M. (2011). Mice Lacking NKT Cells but with a Complete Complement of 
CD8+ T-Cells Are Not Protected against the Metabolic Abnormalities of Diet-
Induced Obesity. PLoS ONE, 6(6), e19831. doi:10.1371/journal.pone.0019831 
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011). Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nature Reviews 
Immunology, 11(8), 519–531. doi:10.1038/nri3024 
89 
 
Marcobal, A., & Sonnenburg, J. L. (2012). Human milk oligosaccharide consumption by 
intestinal microbiota. Clinical Microbiology and Infection, 18, 12–15. 
doi:10.1111/j.1469-0691.2012.03863.x 
Marzullo, P., Minocci, A., Giarda, P., Marconi, C., Tagliaferri, A., Walker, G. E., … 
Liuzzi, A. (2014). Lymphocytes and immunoglobulin patterns across the 
threshold of severe obesity. Endocrine, 45(3), 392–400. doi:10.1007/s12020-013-
0006-z 
Mathis, D., & Shoelson, S. E. (2011). Immunometabolism: an emerging frontier. Nature 
Reviews Immunology, 11(2), 81–83. doi:10.1038/nri2922 
Matsuzawa, Y., Funahashi, T., & Nakamura, T. (2011). The Concept of Metabolic 
Syndrome: Contribution of Visceral Fat Accumulation and Its Molecular 
Mechanism. Journal of Atherosclerosis and Thrombosis, 18(8), 629–639. 
Menghini, R., Marchetti, V., Cardellini, M., Hribal, M. L., Mauriello, A., Lauro, D., … 
Federici, M. (2005). Phosphorylation of GATA2 by Akt Increases Adipose Tissue 
Differentiation and Reduces Adipose Tissue–Related Inflammation A Novel 
Pathway Linking Obesity to Atherosclerosis. Circulation, 111(15), 1946–1953. 
doi:10.1161/01.CIR.0000161814.02942.B2 
Miller, I., Markewitz, B. A., Rolfs, R. T., Brown, S. M., Dascomb, K. K., Grissom, C. K., 
… Dean, N. C. (2010). Clinical findings and demographic factors associated with 
icu admission in utah due to novel 2009 influenza a(h1n1) infection. CHEST 
Journal, 137(4), 752–758. doi:10.1378/chest.09-2517 
90 
 
Miyake, Y., & Yamasaki, S. (2012). Sensing Necrotic Cells. In C. López-Larrea (Ed.), 
Self and Nonself (pp. 144–152). Springer US. Retrieved from 
http://link.springer.com.ezproxy.bu.edu/chapter/10.1007/978-1-4614-1680-7_9 
Monk, J. M., Hou, T. Y., Turk, H. F., Weeks, B., Wu, C., McMurray, D. N., & Chapkin, 
R. S. (2012). Dietary n-3 Polyunsaturated Fatty Acids (PUFA) Decrease Obesity-
Associated Th17 Cell-Mediated Inflammation during Colitis. PLoS ONE, 7(11), 
e49739. doi:10.1371/journal.pone.0049739 
Morelli, M., Gaggini, M., Daniele, G., Marraccini, P., Sicari, R., & Gastaldelli, A. 
(2013). Ectopic fat: the true culprit linking obesity and cardiovascular disease?: 
Thrombosis and Haemostasis, 110(4), 651–660. doi:10.1160/TH13-04-0285 
Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H., … Koyasu, 
S. (2010). Innate production of TH2 cytokines by adipose tissue-associated c-
Kit+Sca-1+ lymphoid cells. Nature, 463(7280), 540–544. 
doi:10.1038/nature08636 
Murray, C. S., Canoy, D., Buchan, I., Woodcock, A., Simpson, A., & Custovic, A. 
(2011). Body mass index in young children and allergic disease: gender 
differences in a longitudinal study. Clinical & Experimental Allergy, 41(1), 78–
85. doi:10.1111/j.1365-2222.2010.03598.x 
Muscari, A., Antonelli, S., Bianchi, G., Cavrini, G., Dapporto, S., Ligabue, A., … Zoli, 
M. (2007). Serum C3 Is a Stronger Inflammatory Marker of Insulin Resistance 
Than C-Reactive Protein, Leukocyte Count, and Erythrocyte Sedimentation Rate 
91 
 
Comparison study in an elderly population. Diabetes Care, 30(9), 2362–2368. 
doi:10.2337/dc07-0637 
Muscari, A., Bozzoli, C., Puddu, G. M., Sangiorgi, Z., Dormi, A., Rovinetti, C., … 
Puddu, P. (1995). Association of serum C3 levels with the risk of myocardial 
infarction. The American Journal of Medicine, 98(4), 357–364. 
doi:10.1016/S0002-9343(99)80314-3 
Mussatto, S. I., & Mancilha, I. M. (2007). Non-digestible oligosaccharides: A review. 
Carbohydrate Polymers, 68(3), 587–597. doi:10.1016/j.carbpol.2006.12.011 
Neel, J. V. (1962). Diabetes Mellitus: A “Thrifty” Genotype Rendered Detrimental by 
“Progress”? American Journal of Human Genetics, 14(4), 353. 
Nelson, J., Billeter, A. T., Seifert, B., Neuhaus, V., Trentz, O., Hofer, C., & Turina, M. 
(2012). Obese trauma patients are at increased risk of early hypovolemic shock: a 
retrospective cohort analysis of 1084 severely injured patients. Critical Care, 
16(3), R77. doi:10.1186/cc11334 
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003). Nonalcoholic steatohepatitis: 
Summary of an AASLD Single Topic Conference. Hepatology, 37(5), 1202–
1219. doi:10.1053/jhep.2003.50193 
Nguyen, K. D., Qiu, Y., Cui, X., Goh, Y. P. S., Mwangi, J., David, T., … Chawla, A. 
(2011). Alternatively activated macrophages produce catecholamines to sustain 
adaptive thermogenesis. Nature, 480(7375), 104–108. doi:10.1038/nature10653 
NIEMAN, D. C., HENSON, D. A., NEHLSEN-CANNARELLA, S. L., EKKENS, M., 
UTTER, A. C., BUTTERWORTH, D. E., & FAGOAGA, O. R. (1999). Influence 
92 
 
of Obesity on Immune Function. Journal of the American Dietetic Association, 
99(3), 294–299. doi:10.1016/S0002-8223(99)00077-2 
NIH. NHLBI. Obesity Guidelines. Body Mass Index Table 1. (n.d.). Retrieved July 24, 
2014, from http://www.nhlbi.nih.gov/guidelines/obesity/bmi_tbl.htm 
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., … Nagai, 
R. (2009). CD8+ effector T cells contribute to macrophage recruitment and 
adipose tissue inflammation in obesity. Nature Medicine, 15(8), 914–920. 
doi:10.1038/nm.1964 
O’Brien, K. B., Vogel, P., Duan, S., Govorkova, E. A., Webby, R. J., McCullers, J. A., & 
Schultz-Cherry, S. (2011). Impaired Wound Healing Predisposes Obese Mice to 
Severe Influenza Virus Infection. Journal of Infectious Diseases, 205(2), 252–
261. doi:10.1093/infdis/jir729 
O’Rourke, R. W., White, A. E., Metcalf, M. D., Olivas, A. S., Mitra, P., Larison, W. G., 
… Marks, D. L. (2011). Hypoxia-induced inflammatory cytokine secretion in 
human adipose tissue stromovascular cells. Diabetologia, 54(6), 1480–1490. 
doi:10.1007/s00125-011-2103-y 
Ohmura, K., Ishimori, N., Ohmura, Y., Tokuhara, S., Nozawa, A., Horii, S., … Tsutsui, 
H. (2010). Natural Killer T Cells Are Involved in Adipose Tissues Inflammation 
and Glucose Intolerance in Diet-Induced Obese Mice. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 30(2), 193–199. 
doi:10.1161/ATVBAHA.109.198614 
93 
 
Okamoto, Y., Kihara, S., Funahashi, T., Matsuzawa, Y., & Libby, P. (2006). 
Adiponectin: a key adipocytokine in metabolic syndrome. Clinical Science, 
110(3), 267. doi:10.1042/CS20050182 
Oñate, B., Vilahur, G., Ferrer-Lorente, R., Ybarra, J., Díez-Caballero, A., Ballesta-López, 
C., … Badimon, L. (2012). The subcutaneous adipose tissue reservoir of 
functionally active stem cells is reduced in obese patients. The FASEB Journal, 
26(10), 4327–4336. doi:10.1096/fj.12-207217 
Ortega, F. B., Lee, D., Katzmarzyk, P. T., Ruiz, J. R., Sui, X., Church, T. S., & Blair, S. 
N. (2013). The intriguing metabolically healthy but obese phenotype: 
cardiovascular prognosis and role of fitness. European Heart Journal, 34(5), 389–
397. doi:10.1093/eurheartj/ehs174 
Osborn, O., & Olefsky, J. M. (2012). The cellular and signaling networks linking the 
immune system and metabolism in disease. Nature Medicine, 18(3), 363–374. 
doi:10.1038/nm.2627 
Ostchega, Y., Hughes, J. P., Terry, A., Fakhouri, T. H. I., & Miller, I. (2012). Abdominal 
Obesity, Body Mass Index, and Hypertension in US Adults: NHANES 2007–
2010. American Journal of Hypertension, 25(12), 1271–1278. 
doi:10.1038/ajh.2012.120 
Ouchi, N., Kihara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., … Matsuzawa, 
Y. (1999). Novel Modulator for Endothelial Adhesion Molecules Adipocyte-
Derived Plasma Protein Adiponectin. Circulation, 100(25), 2473–2476. 
doi:10.1161/01.CIR.100.25.2473 
94 
 
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation 
and metabolic disease. Nature Reviews Immunology, 11(2), 85–97. 
doi:10.1038/nri2921 
Ouchi, N., & Walsh, K. (2007). Adiponectin as an anti-inflammatory factor. Clinica 
Chimica Acta, 380(1–2), 24–30. doi:10.1016/j.cca.2007.01.026 
Palozza, P., Simone, R., Catalano, A., Monego, G., Barini, A., Mele, M. C., … Ranelletti, 
F. O. (2011). Lycopene prevention of oxysterol-induced proinflammatory 
cytokine cascade in human macrophages: inhibition of NF-κB nuclear binding 
and increase in PPARγ expression. The Journal of Nutritional Biochemistry, 
22(3), 259–268. doi:10.1016/j.jnutbio.2010.02.003 
Pang, T. T. L., & Narendran, P. (2008). The Distribution of Adiponectin Receptors on 
Human Peripheral Blood Mononuclear Cells. Annals of the New York Academy of 
Sciences, 1150(1), 143–145. doi:10.1196/annals.1447.021 
Pardo, M., Roca-Rivada, A., Seoane, L. M., & Casanueva, F. F. (2012). Obesidomics: 
contribution of adipose tissue secretome analysis to obesity research. Endocrine, 
41(3), 374–383. doi:10.1007/s12020-012-9617-z 
Pasarica, M., Sereda, O. R., Redman, L. M., Albarado, D. C., Hymel, D. T., Roan, L. E., 
… Smith, S. R. (2008). Reduced Adipose Tissue Oxygenation in Human Obesity: 
Evidence for Rarefaction, Macrophage Chemotaxis, and Inflammation Without an 
Angiogenic Response. Diabetes, 58(3), 718–725. doi:10.2337/db08-1098 
Peinado, J. R., Pardo, M., de la Rosa, O., & Malagón, M. M. (2012). Proteomic 
characterization of adipose tissue constituents, a necessary step for understanding 
95 
 
adipose tissue complexity. PROTEOMICS, 12(4-5), 607–620. 
doi:10.1002/pmic.201100355 
Pérez de Heredia, F., Wood, I. S., & Trayhurn, P. (2010). Hypoxia stimulates lactate 
release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) 
expression in human adipocytes. Pflügers Archiv: European Journal of 
Physiology, 459(3), 509–518. doi:10.1007/s00424-009-0750-3 
Pini, M., & Fantuzzi, G. (2010). Enhanced production of IL-17A during zymosan-
induced peritonitis in obese mice. Journal of Leukocyte Biology, 87(1), 51–58. 
doi:10.1189/jlb.0309188 
Poitou, C., Dalmas, E., Renovato, M., Benhamo, V., Hajduch, F., Abdennour, M., … 
Cremer, I. (2011). CD14dimCD16+ and CD14+CD16+ Monocytes in Obesity 
and During Weight Loss Relationships With Fat Mass and Subclinical 
Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(10), 
2322–2330. doi:10.1161/ATVBAHA.111.230979 
Poitz, D. M., Augstein, A., Hesse, K., Christoph, M., Ibrahim, K., Braun-Dullaeus, R. C., 
… Schmeißer, A. (2014). Regulation of the HIF-system in human macrophages – 
Differential regulation of HIF-α subunits under sustained hypoxia. Molecular 
Immunology, 57(2), 226–235. doi:10.1016/j.molimm.2013.10.001 
Poulos, S. P., Hausman, D. B., & Hausman, G. J. (2010). The development and endocrine 
functions of adipose tissue. Molecular and Cellular Endocrinology, 323(1), 20–
34. doi:10.1016/j.mce.2009.12.011 
96 
 
Preis, S. R., Massaro, J. M., Robins, S. J., Hoffmann, U., Vasan, R. S., Irlbeck, T., … 
Fox, C. S. (2010). Abdominal Subcutaneous and Visceral Adipose Tissue and 
Insulin Resistance in the Framingham Heart Study. Obesity, 18(11), 2191–2198. 
doi:10.1038/oby.2010.59 
Prieur, X., Mok, C. Y. L., Velagapudi, V. R., Núñez, V., Fuentes, L., Montaner, D., … 
Vidal-Puig, A. (2011). Differential Lipid Partitioning Between Adipocytes and 
Tissue Macrophages Modulates Macrophage Lipotoxicity and M2/M1 
Polarization in Obese Mice. Diabetes, 60(3), 797–809. doi:10.2337/db10-0705 
Procaccini, C., De Rosa, V., Galgani, M., Carbone, F., La Rocca, C., Formisano, L., & 
Matarese, G. (2013). Role of adipokines signaling in the modulation of T cells 
function. T Cell Biology, 4, 332. doi:10.3389/fimmu.2013.00332 
Procaccini, C., Jirillo, E., & Matarese, G. (2012). Leptin as an immunomodulator. 
Molecular Aspects of Medicine, 33(1), 35–45. doi:10.1016/j.mam.2011.10.012 
Rabot, S., Membrez, M., Bruneau, A., Gérard, P., Harach, T., Moser, M., … Chou, C. J. 
(2010). Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin 
resistance and have altered cholesterol metabolism. The FASEB Journal, 24(12), 
4948–4959. doi:10.1096/fj.10-164921 
Raetzsch, C. F., Brooks, N. L., Alderman, J. M., Moore, K. S., Hosick, P. A., Klebanov, 
S., … Combs, T. P. (2009). Lipopolysaccharide inhibition of glucose production 
through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear 
factor κb pathway. Hepatology, 50(2), 592–600. doi:10.1002/hep.22999 
97 
 
Rasouli, N., & Kern, P. A. (2008). Adipocytokines and the Metabolic Complications of 
Obesity. The Journal of Clinical Endocrinology & Metabolism, 
93(11_supplement_1), s64–s73. doi:10.1210/jc.2008-1613 
Rasouli, N., Yao-Borengasser, A., Varma, V., Spencer, H. J., McGehee, R. E., Peterson, 
C. A., … Kern, P. A. (2009). Association of Scavenger Receptors in Adipose 
Tissue With Insulin Resistance in Nondiabetic Humans. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 29(9), 1328–1335. 
doi:10.1161/ATVBAHA.109.186957 
Rausch, M. E., Weisberg, S., Vardhana, P., & Tortoriello, D. V. (2007). Obesity in 
C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell 
infiltration. International Journal of Obesity, 32(3), 451–463. 
doi:10.1038/sj.ijo.0803744 
Rijnierse, A., Jeurink, P. V., van Esch, B. C. A. M., Garssen, J., & Knippels, L. M. J. 
(2011). Food-derived oligosaccharides exhibit pharmaceutical properties. 
European Journal of Pharmacology, 668, Supplement 1, S117–S123. 
doi:10.1016/j.ejphar.2011.07.009 
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., … 
Karin, M. (2008). NF-κB links innate immunity to the hypoxic response through 
transcriptional regulation of HIF-1α. Nature, 453(7196), 807–811. 
doi:10.1038/nature06905 
98 
 
Rivero-Urgell, M., & Santamaria-Orleans, A. (2001). Oligosaccharides: application in 
infant food. Early Human Development, 65, Supplement 2, S43–S52. 
doi:10.1016/S0378-3782(01)00202-X 
Robbins, C. S., & Swirski, F. K. (2010). The multiple roles of monocyte subsets in steady 
state and inflammation. Cellular and Molecular Life Sciences: CMLS, 67(16), 
2685–2693. doi:10.1007/s00018-010-0375-x 
Romacho, T., Elsen, M., Röhrborn, D., & Eckel, J. (2014). Adipose Tissue and its Role in 
Organ Crosstalk. Acta Physiologica, n/a–n/a. doi:10.1111/apha.12246 
Rosen, E. D., & Spiegelman, B. M. (2006). Adipocytes as regulators of energy balance 
and glucose homeostasis. Nature, 444(7121), 847–853. doi:10.1038/nature05483 
Rupnick, M. A., Panigrahy, D., Zhang, C.-Y., Dallabrida, S. M., Lowell, B. B., Langer, 
R., & Folkman, M. J. (2002). Adipose tissue mass can be regulated through the 
vasculature. Proceedings of the National Academy of Sciences, 99(16), 10730–
10735. doi:10.1073/pnas.162349799 
Ryan, K. K., & Seeley, R. J. (2013). Food as a Hormone. Science, 339(6122), 918–919. 
doi:10.1126/science.1234062 
Saberi, M., Woods, N.-B., de Luca, C., Schenk, S., Lu, J. C., Bandyopadhyay, G., … 
Olefsky, J. M. (2009). Hematopoietic Cell-Specific Deletion of Toll-like Receptor 
4 Ameliorates Hepatic and Adipose Tissue Insulin Resistance in High-Fat-Fed 
Mice. Cell Metabolism, 10(5), 419–429. doi:10.1016/j.cmet.2009.09.006 
99 
 
Sacks, H. S., & Fain, J. N. (2011). Human epicardial fat: what is new and what is 
missing? Clinical & Experimental Pharmacology & Physiology, 38(12), 879–887. 
doi:10.1111/j.1440-1681.2011.05601.x 
Saliba, W., Barnett-Griness, O., & Rennert, G. (2013). The association between obesity 
and urinary tract infection. European Journal of Internal Medicine, 24(2), 127–
131. doi:10.1016/j.ejim.2012.11.006 
Samocha-Bonet, D., Chisholm, D. J., Tonks, K., Campbell, L. V., & Greenfield, J. R. 
(2012). Insulin-sensitive obesity in humans – a “favorable fat” phenotype? Trends 
in Endocrinology & Metabolism, 23(3), 116–124. doi:10.1016/j.tem.2011.12.005 
Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., … Lusis, A. J. 
(2005). An integrative genomics approach to infer causal associations between 
gene expression and disease. Nature Genetics, 37(7), 710–717. 
doi:10.1038/ng1589 
Schaffer, J. (2003). Lipotoxicity: when tissues overeat. Current Opinion in Lipidology 
June 2003, 14(3), 281–287. 
Schäffler, A., & Schölmerich, J. (2010). Innate immunity and adipose tissue biology. 
Trends in Immunology, 31(6), 228–235. doi:10.1016/j.it.2010.03.001 
Schipper, H. S., Prakken, B., Kalkhoven, E., & Boes, M. (2012). Adipose tissue-resident 
immune cells: key players in immunometabolism. Trends in Endocrinology & 
Metabolism, 23(8), 407–415. doi:10.1016/j.tem.2012.05.011 
Scientific REgistry of Transplant Recipients. Table 9.1C. Waiting List Patient 
Characteristics at Year-End Liver Waiting List. All Waitlist Patients, 2002-2011. 
100 
 
(n.d.). Retrieved July 25, 2014, from 
http://www.srtr.org/annual_Reports/2011/901c_can-dgn_li.aspx 
Sekitani, Y., Hayashida, N., Kadota, K., Yamasaki, H., Abiru, N., Nakazato, M., … 
Takamura, N. (2010). White blood cell count and cardiovascular biomarkers of 
atherosclerosis. Biomarkers: Biochemical Indicators of Exposure, Response, and 
Susceptibility to Chemicals, 15(5), 454–460. doi:10.3109/1354750X.2010.486870 
Semenza, G. L. (1998). Hypoxia-inducible factor 1: master regulator of O2 homeostasis. 
Current Opinion in Genetics & Development, 8(5), 588–594. doi:10.1016/S0959-
437X(98)80016-6 
Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 
3(10), 721–732. doi:10.1038/nrc1187 
Semenza, G. L. (2011). Regulation of Metabolism by Hypoxia-Inducible Factor 1. Cold 
Spring Harbor Symposia on Quantitative Biology, 76, 347–353. 
doi:10.1101/sqb.2011.76.010678 
Semins, M. J., Shore, A. D., Makary, M. A., Weiner, J., & Matlaga, B. R. (2012). The 
Impact of Obesity on Urinary Tract Infection Risk. Urology, 79(2), 266–269. 
doi:10.1016/j.urology.2011.09.040 
Shetty, S., Kusminski, C. M., & Scherer, P. E. (2009). Adiponectin in health and disease: 
evaluation of adiponectin-targeted drug development strategies. Trends in 
Pharmacological Sciences, 30(5), 234–239. doi:10.1016/j.tips.2009.02.004 
Shin, M.-K., Drager, L. F., Yao, Q., Bevans-Fonti, S., Yoo, D.-Y., Jun, J. C., … Polotsky, 
V. Y. (2012). Metabolic Consequences of High-Fat Diet Are Attenuated by 
101 
 
Suppression of HIF-1α. PLoS ONE, 7(10), e46562. 
doi:10.1371/journal.pone.0046562 
Simonsen, L., Spreeuwenberg, P., Lustig, R., Taylor, R. J., Fleming, D. M., Kroneman, 
M., … the GLaMOR Collaborating Teams. (2013). Global Mortality Estimates 
for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study. 
PLoS Med, 10(11), e1001558. doi:10.1371/journal.pmed.1001558 
Sironi, A. M., Petz, R., De Marchi, D., Buzzigoli, E., Ciociaro, D., Positano, V., … 
Gastaldelli, A. (2012). Impact of increased visceral and cardiac fat on 
cardiometabolic risk and disease. Diabetic Medicine, 29(5), 622–627. 
doi:10.1111/j.1464-5491.2011.03503.x 
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007). Relationship between 
Adipocyte Size and Adipokine Expression and Secretion. The Journal of Clinical 
Endocrinology & Metabolism, 92(3), 1023–1033. doi:10.1210/jc.2006-1055 
Smith, A. G., Sheridan, P. A., Harp, J. B., & Beck, M. A. (2007). Diet-Induced Obese 
Mice Have Increased Mortality and Altered Immune Responses When Infected 
with Influenza Virus. The Journal of Nutrition, 137(5), 1236–1243. 
Snel, M., Jonker, J. T., Schoones, J., Lamb, H., de Roos, A., Pijl, H., … Jazet, I. M. 
(2012). Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet 
and Lifestyle Interventions. International Journal of Endocrinology, 2012. 
doi:10.1155/2012/983814 
Sorisky, A., Molgat, A. S. D., & Gagnon, A. (2013). Macrophage-Induced Adipose 
Tissue Dysfunction and the Preadipocyte: Should I Stay (and Differentiate) or 
102 
 
Should I Go? Advances in Nutrition: An International Review Journal, 4(1), 67–
75. doi:10.3945/an.112.003020 
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, 
O., … Arner, P. (2008). Dynamics of fat cell turnover in humans. Nature, 
453(7196), 783–787. doi:10.1038/nature06902 
Spencer, M., Unal, R., Zhu, B., Rasouli, N., McGehee, R. E., Peterson, C. A., & Kern, P. 
A. (2011). Adipose Tissue Extracellular Matrix and Vascular Abnormalities in 
Obesity and Insulin Resistance. The Journal of Clinical Endocrinology & 
Metabolism, 96(12), E1990–E1998. doi:10.1210/jc.2011-1567 
Stefan N, Kantartzis K, Machann J, & et al. (2008). Identification and characterization of 
metabolically benign obesity in humans. Archives of Internal Medicine, 168(15), 
1609–1616. doi:10.1001/archinte.168.15.1609 
Strawford, A., Antelo, F., Christiansen, M., & Hellerstein, M. K. (2004). Adipose tissue 
triglyceride turnover, de novo lipogenesis, and cell proliferation in humans 
measured with 2H2O. American Journal of Physiology - Endocrinology and 
Metabolism, 286(4), E577–E588. doi:10.1152/ajpendo.00093.2003 
Sugawara, Y., & Makuuchi, M. (2006). Living donor liver transplantation to patients with 
hepatitis C virus cirrhosis. World Journal of Gastroenterology: WJG, 12(28), 
4461–4465. 
Sun, K., Halberg, N., Khan, M., Magalang, U. J., & Scherer, P. E. (2013). Selective 
Inhibition of Hypoxia-Inducible Factor 1 Ameliorates Adipose Tissue 
103 
 
Dysfunction. Molecular and Cellular Biology, 33(5), 904–917. 
doi:10.1128/MCB.00951-12 
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011). Adipose tissue remodeling and 
obesity. Journal of Clinical Investigation, 121(6), 2094–2101. 
doi:10.1172/JCI45887 
Suvan, J., D’Aiuto, F., Moles, D. R., Petrie, A., & Donos, N. (2011). Association 
between overweight/obesity and periodontitis in adults. A systematic review. 
Obesity Reviews, 12(5), e381–e404. doi:10.1111/j.1467-789X.2010.00808.x 
Suzuki, M., Shinohara, Y., Ohsaki, Y., & Fujimoto, T. (2011). Lipid droplets: size 
matters. Journal of Electron Microscopy, 60(suppl 1), S101–S116. 
doi:10.1093/jmicro/dfr016 
Syn, W.-K., Htun Oo, Y., Pereira, T. A., Karaca, G. F., Jung, Y., Omenetti, A., … Diehl, 
A. M. (2010). Accumulation of natural killer T cells in progressive nonalcoholic 
fatty liver disease. Hepatology, 51(6), 1998–2007. doi:10.1002/hep.23599 
Tadros, T. M., Massaro, J. M., Rosito, G. A., Hoffmann, U., Vasan, R. S., Larson, M. G., 
… Benjamin, E. J. (2010). Pericardial Fat Volume Correlates With Inflammatory 
Markers: The Framingham Heart Study. Obesity, 18(5), 1039–1045. 
doi:10.1038/oby.2009.343 
Taylor, C. T. (2008). Interdependent roles for hypoxia inducible factor and nuclear 
factor-κB in hypoxic inflammation. The Journal of Physiology, 586(17), 4055–
4059. doi:10.1113/jphysiol.2008.157669 
104 
 
Tchoukalova, Y., Koutsari, C., & Jensen, M. (2007). Committed subcutaneous 
preadipocytes are reduced in human obesity. Diabetologia, 50(1), 151–157. 
doi:10.1007/s00125-006-0496-9 
The World Bank. Population, total | Data Table. (n.d.). Retrieved July 24, 2014, from 
http://data.worldbank.org/indicator/SP.POP.TOTL 
Tilg, H., & Kaser, A. (2011). Gut microbiome, obesity, and metabolic dysfunction. 
Journal of Clinical Investigation, 121(6), 2126–2132. doi:10.1172/JCI58109 
Touyz, R. M., & Schiffrin, E. L. (2006). Peroxisome proliferator-activated receptors in 
vascular biology-molecular mechanisms and clinical implications. Vascular 
Pharmacology, 45(1), 19–28. doi:10.1016/j.vph.2005.11.014 
Tran, T. T., Yamamoto, Y., Gesta, S., & Kahn, C. R. (2008). Beneficial Effects of 
Subcutaneous Fat Transplantation on Metabolism. Cell Metabolism, 7(5), 410–
420. doi:10.1016/j.cmet.2008.04.004 
Trayhurn, P. (2013). Hypoxia and Adipose Tissue Function and Dysfunction in Obesity. 
Physiological Reviews, 93(1), 1–21. doi:10.1152/physrev.00017.2012 
Trayhurn, P., & Wood, I. S. (2004). Adipokines: inflammation and the pleiotropic role of 
white adipose tissue. British Journal of Nutrition, 92(03), 347–355. 
doi:10.1079/BJN20041213 
Tsang, J. Y. S., Li, D., Ho, D., Peng, J., Xu, A., Lamb, J., … Tam, P. K. H. (2011). Novel 
immunomodulatory effects of adiponectin on dendritic cell functions. 
International Immunopharmacology, 11(5), 604–609. 
doi:10.1016/j.intimp.2010.11.009 
105 
 
Tsatsoulis, A., Mantzaris, M. D., Bellou, S., & Andrikoula, M. (2013). Insulin resistance: 
An adaptive mechanism becomes maladaptive in the current environment — An 
evolutionary perspective. Metabolism, 62(5), 622–633. 
doi:10.1016/j.metabol.2012.11.004 
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., … 
Charo, I. F. (2007). Critical roles for CCR2 and MCP-3 in monocyte mobilization 
from bone marrow and recruitment to inflammatory sites. Journal of Clinical 
Investigation, 117(4), 902–909. doi:10.1172/JCI29919 
Unger, R. H. (2005). Longevity, lipotoxicity and leptin: the adipocyte defense against 
feasting and famine. Biochimie, 87(1), 57–64. doi:10.1016/j.biochi.2004.11.014 
Unger, R. H., & Scherer, P. E. (2010). Gluttony, sloth and the metabolic syndrome: a 
roadmap to lipotoxicity. Trends in Endocrinology & Metabolism, 21(6), 345–352. 
doi:10.1016/j.tem.2010.01.009 
Van Greevenbroek, M. M. J., Jacobs, M., van der Kallen, C. J. H., Vermeulen, V. M. M.-
J., Jansen, E. H. J. M., Schalkwijk, C. G., … Stehouwer, C. D. A. (2011). The 
cross-sectional association between insulin resistance and circulating complement 
C3 is partly explained by plasma alanine aminotransferase, independent of central 
obesity and general inflammation (the CODAM study). European Journal of 
Clinical Investigation, 41(4), 372–379. doi:10.1111/j.1365-2362.2010.02418.x 
Van Kerkhove, M. D., Vandemaele, K. A. H., Shinde, V., Jaramillo-Gutierrez, G., 
Koukounari, A., Donnelly, C. A., … on behalf of the WHO Working Group for 
Risk Factors for Severe H1N1pdm Infection. (2011). Risk Factors for Severe 
106 
 
Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled 
Analysis. PLoS Med, 8(7), e1001053. doi:10.1371/journal.pmed.1001053 
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., 
… Dixit, V. D. (2011). The NLRP3 inflammasome instigates obesity-induced 
inflammation and insulin resistance. Nature Medicine, 17(2), 179–188. 
doi:10.1038/nm.2279 
Vasudevan, A. R., Wu, H., Xydakis, A. M., Jones, P. H., Smith, E. O., Sweeney, J. F., … 
Ballantyne, C. M. (2006). Eotaxin and obesity. The Journal of Clinical 
Endocrinology and Metabolism, 91(1), 256–261. doi:10.1210/jc.2005-1280 
Viasus, D., Paño-Pardo, J. R., Pachón, J., Campins, A., López-Medrano, F., Villoslada, 
A., … (reipi),  for the N. I. A. (H1N1) S. G. of the S. N. for R. in I. D. (2011). 
Factors associated with severe disease in hospitalized adults with pandemic 
(H1N1) 2009 in Spain. Clinical Microbiology and Infection, 17(5), 738–746. 
doi:10.1111/j.1469-0691.2010.03362.x 
Virtanen, K. A., Lönnroth, P., Parkkola, R., Peltoniemi, P., Asola, M., Viljanen, T., … 
Nuutila, P. (2002). Glucose uptake and perfusion in subcutaneous and visceral 
adipose tissue during insulin stimulation in nonobese and obese humans. The 
Journal of Clinical Endocrinology and Metabolism, 87(8), 3902–3910. 
doi:10.1210/jcem.87.8.8761 
Virtue, S., & Vidal-Puig, A. (2008). It’s Not How Fat You Are, It’s What You Do with It 
That Counts. PLoS Biol, 6(9), e237. doi:10.1371/journal.pbio.0060237 
107 
 
Visness, C. M., London, S. J., Daniels, J. L., Kaufman, J. S., Yeatts, K. B., Siega-Riz, A.-
M., … Zeldin, D. C. (2009). Association of obesity with IgE levels and allergy 
symptoms in children and adolescents: Results from the National Health and 
Nutrition Examination Survey 2005-2006. Journal of Allergy and Clinical 
Immunology, 123(5), 1163–1169.e4. doi:10.1016/j.jaci.2008.12.1126 
Wang, B., Wood, I. S., & Trayhurn, P. (2008). Hypoxia induces leptin gene expression 
and secretion in human preadipocytes: differential effects of hypoxia on adipokine 
expression by preadipocytes. Journal of Endocrinology, 198(1), 127–134. 
doi:10.1677/JOE-08-0156 
Wang Y, W. Q. (2004). The prevalence of prehypertension and hypertension among us 
adults according to the new joint national committee guidelines: New challenges 
of the old problem. Archives of Internal Medicine, 164(19), 2126–2134. 
doi:10.1001/archinte.164.19.2126 
Wang, Y.-Y., Lin, S.-Y., Sheu, W. H.-H., Liu, P.-H., & Tung, K.-C. (2010). Obesity and 
diabetic hyperglycemia were associated with serum alanine aminotransferase 
activity in patients with hepatitis B infection. Metabolism, 59(4), 486–491. 
doi:10.1016/j.metabol.2009.07.038 
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., … Jr., A. 
W. F. (2006). CCR2 modulates inflammatory and metabolic effects of high-fat 
feeding. Journal of Clinical Investigation, 116(1), 115–124. 
doi:10.1172/JCI24335 
108 
 
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. 
W. (2003). Obesity is associated with macrophage accumulation in adipose tissue. 
Journal of Clinical Investigation, 112(12), 1796–1808. 
doi:10.1172/JCI200319246 
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., … Ting, J. P.-Y. (2011). 
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin 
signaling. Nature Immunology, 12(5), 408–415. doi:10.1038/ni.2022 
Wen, H., Ting, J. P.-Y., & O’Neill, L. A. J. (2012). A role for the NLRP3 inflammasome 
in metabolic diseases—did Warburg miss inflammation? Nature Immunology, 
13(4), 352–357. doi:10.1038/ni.2228 
Westcott, D. J., DelProposto, J. B., Geletka, L. M., Wang, T., Singer, K., Saltiel, A. R., & 
Lumeng, C. N. (2009). MGL1 promotes adipose tissue inflammation and insulin 
resistance by regulating 7/4hi monocytes in obesity. The Journal of Experimental 
Medicine, 206(13), 3143–3156. doi:10.1084/jem.20091333 
White, U. A., & Tchoukalova, Y. D. (2012). Implications of 2H-labeling of DNA 
protocol to measure in vivo cell turnover in adipose tissue. Adipocyte, 1(4), 242–
245. doi:10.4161/adip.20817 
WHOa | Nutrition. Controlling the global obesity epidemic. (n.d.). Retrieved July 26, 
2014, from http://www.who.int/nutrition/topics/obesity/en/ 
WHOb | Global Health Observatory (GHO). Obesity. Situation and trends. (n.d.). WHO. 
Retrieved July 24, 2014, from 
http://www.who.int/gho/ncd/risk_factors/obesity_text/en/ 
109 
 
WHOc | Weekly Virological Update on 12 August 2010. (n.d.). WHO. Retrieved June 11, 
2013, from 
http://www.who.int/csr/disease/swineflu/laboratory13_08_2010/en/index.html 
WHOd | Global Alert and Response (GAR). Pandemic (H1N1) 2009 - update 112", n.d.).
 Retrieved June 11, 2013, fromhttp://www.who.int/csr/don/2010_07_30/en/ 
Wiegand, J., & Berg, T. (2013). The etiology, diagnosis and prevention of liver cirrhosis: 
part 1 of a series on liver cirrhosis. Deutsches Ärzteblatt International, 110(6), 
85–91. doi:10.3238/arztebl.2013.0085 
Wiesner, R. H., Sorrell, M., & Villamil, F. (2003). Report of the First International Liver 
Transplantation Society Expert Panel Consensus Conference on Liver 
Transplantation and Hepatitis C. Liver Transplantation, 9(11), S1–S9. 
doi:10.1053/jlts.2003.50268 
Wilk, S., Scheibenbogen, C., Bauer, S., Jenke, A., Rother, M., Guerreiro, M., … Skurk, 
C. (2011). Adiponectin is a negative regulator of antigen-activated T cells. 
European Journal of Immunology, 41(8), 2323–2332. doi:10.1002/eji.201041349 
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., … Dosch, H.-M. 
(2009). Normalization of obesity-associated insulin resistance through 
immunotherapy. Nature Medicine, 15(8), 921–929. doi:10.1038/nm.2001 
Winfield, R. D., Delano, M. J., Cuenca, A. G., Cendan, J. C., Lottenberg, L., Efron, P. A., 
… Cuschieri, J. (2012). Obese Patients Show a Depressed Cytokine Profile 
Following Severe Blunt Injury. Shock, 37(3), 253–256. 
doi:10.1097/SHK.0b013e3182449c0e 
110 
 
Winfield, R. D., Delano, M. J., Dixon, D. J., Schierding, W. S., Cendan, J. C., 
Lottenberg, L., … Cuschieri, J. (2010). Differences in outcome between obese 
and nonobese patients following severe blunt trauma are not consistent with an 
early inflammatory genomic response. Critical Care Medicine, 38(1), 51–58. 
doi:10.1097/CCM.0b013e3181b08089 
Winfield, R. D., Delano, M. J., Lottenberg, L., Cendan, J. C., Moldawer, L. L., Maier, R. 
V., & Cuschieri, J. (2010). Traditional resuscitative practices fail to resolve 
metabolic acidosis in morbidly obese patients after severe blunt trauma. The 
Journal of Trauma, 68(2), 317–330. doi:10.1097/TA.0b013e3181caab6c 
Winther, M. P. J. de, Kanters, E., Kraal, G., & Hofker, M. H. (2005). Nuclear Factor κB 
Signaling in Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 
25(5), 904–914. doi:10.1161/01.ATV.0000160340.72641.87 
Wolf, A. M., Wolf, D., Rumpold, H., Enrich, B., & Tilg, H. (2004). Adiponectin induces 
the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. 
Biochemical and Biophysical Research Communications, 323(2), 630–635. 
doi:10.1016/j.bbrc.2004.08.145 
Wong, G. L.-H., Wong, V. W.-S., Choi, P. C.-L., Chan, A. W.-H., Chim, A. M.-L., Yiu, 
K. K.-L., … Chan, H. L.-Y. (2009). Metabolic syndrome increases the risk of 
liver cirrhosis in chronic hepatitis B. Gut, 58(1), 111–117. 
doi:10.1136/gut.2008.157735 
111 
 
Wood, I. S., de Heredia, F. P., Wang, B., & Trayhurn, P. (2009). Cellular hypoxia and 
adipose tissue dysfunction in obesity. Proceedings of the Nutrition Society, 
68(04), 370–377. doi:10.1017/S0029665109990206 
Wood, I. S., Stezhka, T., & Trayhurn, P. (2011). Modulation of adipokine production, 
glucose uptake and lactate release in human adipocytes by small changes in 
oxygen tension. Pflügers Archiv: European Journal of Physiology, 462(3), 469–
477. doi:10.1007/s00424-011-0985-7 
Wu, D., Molofsky, A. B., Liang, H.-E., Ricardo-Gonzalez, R. R., Jouihan, H. A., Bando, 
J. K., … Locksley, R. M. (2011). Eosinophils Sustain Adipose Alternatively 
Activated Macrophages Associated with Glucose Homeostasis. Science, 
332(6026), 243–247. doi:10.1126/science.1201475 
Wu, H., Ghosh, S., Perrard, X. D., Feng, L., Garcia, G. E., Perrard, J. L., … Ballantyne, 
C. M. (2007). T-Cell Accumulation and Regulated on Activation, Normal T Cell 
Expressed and Secreted Upregulation in Adipose Tissue in Obesity. Circulation, 
115(8), 1029–1038. doi:10.1161/CIRCULATIONAHA.106.638379 
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., … Chen, H. (2003). 
Chronic inflammation in fat plays a crucial role in the development of obesity-
related insulin resistance. Journal of Clinical Investigation, 112(12), 1821–1830. 
doi:10.1172/JCI200319451 
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., … Kadowaki, T. 
(2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic 
effects. Nature, 423(6941), 762–769. doi:10.1038/nature01705 
112 
 
Yang, H., Youm, Y.-H., Vandanmagsar, B., Rood, J., Kumar, K. G., Butler, A. A., & 
Dixit, V. D. (2009). Obesity accelerates thymic aging. Blood, 114(18), 3803–
3812. doi:10.1182/blood-2009-03-213595 
Yau, P. L., Kang, E. H., Javier, D. C., & Convit, A. (2014). Preliminary evidence of 
cognitive and brain abnormalities in uncomplicated adolescent obesity. Obesity 
(Silver Spring, Md.). doi:10.1002/oby.20801 
Yun, Z., Maecker, H. L., Johnson, R. S., & Giaccia, A. J. (2002). Inhibition of PPARγ2 
Gene Expression by the HIF-1-Regulated Gene DEC1/Stra13: A Mechanism for 
Regulation of Adipogenesis by Hypoxia. Developmental Cell, 2(3), 331–341. 
doi:10.1016/S1534-5807(02)00131-4 
Zhang, X., & Mosser, D. (2008). Macrophage activation by endogenous danger signals. 
The Journal of Pathology, 214(2), 161–178. doi:10.1002/path.2284 
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994). 
Positional cloning of the mouse obese gene and its human homologue. Nature, 
372(6505), 425–432. doi:10.1038/372425a0 
Zhao, Y., Joshi-Barve, S., Barve, S., & Chen, L. H. (2004). Eicosapentaenoic Acid 
Prevents LPS-Induced TNF-α Expression by Preventing NF-κB Activation. 
Journal of the American College of Nutrition, 23(1), 71–78. 
doi:10.1080/07315724.2004.10719345 
Zhao, Y., Sun, R., You, L., Gao, C., & Tian, Z. (2003). Expression of leptin receptors and 
response to leptin stimulation of human natural killer cell lines. Biochemical and 
113 
 
Biophysical Research Communications, 300(2), 247–252. doi:10.1016/S0006-
291X(02)02838-3 
Zhou, S., Lechpammer, S., Greenberger, J. S., & Glowacki, J. (2005). Hypoxia Inhibition 
of Adipocytogenesis in Human Bone Marrow Stromal Cells Requires 
Transforming Growth Factor-β/Smad3 Signaling. Journal of Biological 
Chemistry, 280(24), 22688–22696. doi:10.1074/jbc.M412953200 
Ziaja, J., Król, R., Pawlicki, J., Heitzman, M., Wilk, J., Kowalik, A., … Cierpka, L. 
(2011). Donor-Dependent Risk Factors for Early Surgical Complications After 
Simultaneous Pancreas–Kidney Transplantation. Transplantation Proceedings, 
43(8), 3092–3096. doi:10.1016/j.transproceed.2011.08.072 
  
114 
 
VITA 
 
ROMAN FAYNGERSH 
romafa@gmail.com • 617-515-1335 • DOB: 1974 
941 Lagrange St, West Roxbury, MA 02132 
 
EDUCATION   
BOSTON UNIVERSITY SCHOOL OF MEDICINE, CURRENT 
  Masters of Science in Medical Sciences 
 BOSTON UNIVERSITY,       2008-2010 
  Post-Baccalaureate courses 
BOSTON COLLEGE,       2008 
  Post-Baccalaureate courses 
BENTLEY COLLEGE,       1992-1996 
  B.S. Degree, Economics and Finance,    06/96 
Delta Kappa Epsilon Fraternity – Member 
 
EXPERIENCE  
 
First International Holding Group, LLC.  Owner - 01/03 to 09/10 
Trading firm importing and exporting heavy construction equipment and 
tractor trailers. 
 
• Run daily operation. 
• Customers in China, Russia, Ukraine, Moldova, Latvia. 
 
Empirix, Inc., Sales Representative/Sales Manager - 03/00 to 10/02 
Empirix makes quality control and monitoring software for small and large size 
businesses. Sales ranged from $30k to $150k.  
 
• 2000 Achieved yearly sales quota in 9 months. 
• 2001 Awarded 8,000 Stock Options for outstanding performance. 
• 2001 Promoted to a Sales Manager running a group of 5 Sales 
Representatives. 
• All sales were in a Business to Business environment, where purchase 
dollars came from Capital Budgets. 
• Results achieved through “needs based problem resolutions” and 
consultative sales techniques. 
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• Interacted with QA Managers, Sales VPs and Directors, Accounting and 
Finance Managers to cultivate champions and build a team consensus. 
• Complex and involved sales cycles begun at the engineering level, while 
final negotiations always took place with a “C” level executive. 
 
Parametric Technology Corp., Inside Sales Representative - 11/98 to 03/00 
PTC is a product development company. 
 
• 1999 Generated in excess of 130% of the quota. 
• All product sales were performed in a Business to Business environment. 
• Responsible for commercial, as well as, federal government accounts 
(NASA, JPL, Lawrence Livermore Labs), which required thorough 
understanding of complex bureaucratic and financial relationships. 
• Responsible for providing support to my outside sales representatives, 
while also spearheading efforts in uncovering additional demand from 
existing accounts. 
• Responsible for providing customer support, ranging from technical help to 
the financial questions and training issues. 
• Ability to multitask was crucial to succeed in this position. 
 
Brown & Co, Trader - 09/97 to 11/98 
Brown is a financial services firm dealing with stocks, bonds and options 
trading. 
 
• Responsible for extremely fast dispute resolution of highly complex issues 
pertaining to options trading transactions. 
• Worked collaboratively in a team environment. 
• Served as a liaison, negotiating between the exchange floor traders, 
managers and finance departments to bring about a win-win resolution. 
Merrill Lynch & Co, Financial Consultant - 08/96 to 09/97 
 
• Passed my Federal Financial Certification (Series 7 Exam) on the first try. 
• 1996-‘97 managed $7 million dollars. 
• 1996-‘97 expanded client base from 0 to 38 qualified relationships. 
• Portfolio analysis and risk assessment and options trading strategies. 
• Conducted “Cold-Calls” on daily bases to uncover new business. 
 
 
OTHER SKILLS Fluent in Russian (speaking, reading & writing). 
 
 
